WO2005005668A2 - Methodes de diagnostic et de traitement se rapportant au vieillissement (8a) - Google Patents

Methodes de diagnostic et de traitement se rapportant au vieillissement (8a) Download PDF

Info

Publication number
WO2005005668A2
WO2005005668A2 PCT/US2004/021944 US2004021944W WO2005005668A2 WO 2005005668 A2 WO2005005668 A2 WO 2005005668A2 US 2004021944 W US2004021944 W US 2004021944W WO 2005005668 A2 WO2005005668 A2 WO 2005005668A2
Authority
WO
WIPO (PCT)
Prior art keywords
protein
human
age
clone
mouse
Prior art date
Application number
PCT/US2004/021944
Other languages
English (en)
Other versions
WO2005005668A3 (fr
Inventor
John J. Kopchick
Markus Riders
Karen T. Coschigano
Elahu S. Gosney
Original Assignee
Ohio University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio University filed Critical Ohio University
Priority to CA002531420A priority Critical patent/CA2531420A1/fr
Priority to EP04777802A priority patent/EP1649063A2/fr
Publication of WO2005005668A2 publication Critical patent/WO2005005668A2/fr
Publication of WO2005005668A3 publication Critical patent/WO2005005668A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • mice with a disrupted growth hormone receptor/binding protein gene enjoy an increased lifespan.
  • U.S. Prov. Appl. 60/485,222 filed July 8, 2003 (Kopchick ⁇ ) mouse genes differentially expressed in comparisons of gene expression in growth hormone receptor/binding protein gene-disrupted mouse livers and normal mouse livers were identified, as were corresponding human genes and proteins. It was suggested that the human molecules, or antagonists thereof, could be used for protection against faster-than-normal biological aging, or to achieve slower-than-normal biological aging. It was also taught that the human molecules may also be used as markers of biological aging. In provisional application Ser. No.
  • mice 60/474,606, filed June 2, 2003 (our docket Kopchick7-USA)
  • our research group used a gene chip to study the genetic changes in the liver of C57B1/6J mice that occur at frequent intervals of the aging process.
  • Differential hybridization techniques were used to identify mouse genes that are differentially expressed in mice, depending upon their age.
  • RNA derived from mice of different ages was screened for hybridization with oligonucleotide probes each specific to a particular mouse gene, each gene in turn representative of a particular mouse gene cluster (Unigene) .
  • Related human genes and proteins were identified by sequence comparisons to the mouse gene or protein.
  • Kopchick7A-PCT filed June 2, 2004, we added some additional studies of CIDE-A (see below) .
  • the effect of aging on the expression of genes in mouse skeletal muscle was studied, see provisional application Ser. No. 60/566,068, filed April 29, 2004 (our docket Kopchickl4-USA) .
  • RNA derived from RNA of mouse liver, was screened against a mouse gene chip. See also 60/506,716, filed Sept. 30, 2003 (Kopchick6.1) . Gene chip analyses have also been used to identify genes differentially expressed in normal vs. hyperinsulinemic, hyperinsulinemic vs. type II diabetic, or normal vs. type II diabetic mouse pancreas, see U.S. Provisional Appl. 60/517,376, filed Nov. 6, 2003 (Kopchickl2) and muscle, see U.S Provisional Appl. 60/547,512, filed Feb. 26, 2004 (Kopchickl5) . Other differential hybridization applications . The use of differential hybridization to identify genes and proteins is also described in our research group's Ser. No.
  • the invention relates to various nucleic acid molecules and proteins, and their use in (1) diagnosing aging, or adverse conditions associated with the aging process, and (2) protecting mammals (including humans) against the aging process or adverse conditions associated with the aging process .
  • a second C. elegans gene, clk-1 has also been linked to the reduction of ROS and an extended life-span. While the effect of daf-2 mutants result in a reduction of mitochondrial ROS, clk-1 mutants reduce extramitochondrially produced ROS. Since the majority of cellular ROS is produce in the mitochondria during the process of electron transport, it is not surprising that clk-1 mutants have only a moderately extended life-span. C. elegans containing daf- 2 /clk-1 double mutations, however, exhibit a very long life- span (13) . Decreased IGF-1 signaling may also extend longevity in mice. Four mouse models with deficiencies in pituitary endocrine action have demonstrated retarded aging.
  • GHR- KO growth hormone receptor
  • mice also exhibit reduced body size and extended life-span and more directly implicates the GH/IGF-1 axis (17, 17a) .
  • IGF-1 receptor signaling was provided by the targeted disruption of the IGR-1 receptor (Igflr) (18) .
  • Igflr IGR-1 receptor
  • Tyrosine phosphorylation of the intracellular signaling molecule, She was also decreased in the Igflr + ⁇ females.
  • mice containing the targeted deletion of p66shc also have increased resistance to oxidative stress and a 30% increase in life span (19) . While the IGF-1 axis appears to be involved in the aging process, the mechanism by which it does so remains unknown. However, these findings demonstrate that it is possible to identify specific genetic pathways that affect the aging process . The finding that caloric restriction of these mouse models can further extend their life-span suggests that multiple pathways exist that affect the aging process (20) . Therefore, research to identify these pathways and the genes involved in the aging process is of great importance.
  • the proteins which were over-expressed in the older rat were glucose-6- phosphate isomerase (xl.8), pyruvate kinase (x4.8), hepatic product spot 14 (2.4x), fatty acid synthase (1.9x), staryl CoA desaturase (1.7x), enoyl CoA hyydratase (1.7x), peroxisome proliferator activated receptor- ⁇ (1.7x), 3- ketoacyl-CoA thiolase (1.7x), 3-keto-acyl-CoA peroxisomal thiolase (1.9x), CYP4A3 (3.3x), glycerol-3 -phosphate dehydrogenase (1.7x), NAPDH-cytochrome P450 oxidoreductase (4.7x).
  • CUP2C7 (1.9x), CYP3A2 (2.8x), ⁇ -aminoevulinate synthase (2.3x) .
  • the under-expressed proteins were glucose- 6-phosphatase (0.3x), farnesyl pyrophosphate synthase (0.5x), carnitine octanoyltransferase (0.5x), mitochrondrial genome (16S ribosomal RNA) (0.3x), mitochondrial cytochrome c oxidase II (0.4x), mitochondrial NADH dehydrogenase SU 5 (0.3x), mitochondrial cytochrome b (0.4x), mitochondrial NADH dhydrogenase SU 3 ' (0.5x), NADH-ubiquinone oxidoreductase (SU CI-SGDH and SU 39kDa) (both 0.5x) , ubiquinol-cytochrome c reductase (Rieske iron-sulfur protein and core 1) (both 0.5x)
  • Kidney androgen-regulated protein gene was used as a positive control, as it is known to be up-regulated by DHT. See also Holland, et al . , Abstract 607, "Identification of Genes Possibly Involved in Nephropathy of Bovine Growth Hormone Transgenic Mice” (Endocrine Society Meeting, June 22, 2000) and Coschigano, et al . , Abstract 333, "Identification of Genes Potentially Involved in Kidney
  • differential hybridization articles may also be of interest: Wada, et al . , "Gene expression profile in streptozotocin-induced diabetic mice kidneys undergoing glomerulosclerosis” , Kidney Int, 59:1363-73 (2001); Song, et al . , "Cloning of a novel gene in the human kidney homologous to rat muncl3S: its potential role in diabetic nephropathy", Kidney Int., 53:1689-95 (1998); Page, et al . , “Isolation of diabetes-associated kidney genes using differential display", Biochem. Biophys. Res. Comm.
  • Patents of possible interest include the following:
  • Apoptosis and CIDE-A Apoptosis is a form of programmed cell death that occurs in an active and controlled manner to eliminate unwanted cells.
  • Apoptotic cells undergo an orchestrated cascade of morphological changes such as membrane blebbing, nuclear shrinkage, chromatin condensation, and formation of apoptotic bodies which then undergo phagocytosis by neighboring cells.
  • One of the hallmarks of cellular apoptosis is the cleavage of chromosomal DNA into discrete oligonucleosomal size fragments. This orderly removal of unwanted cells minimizes the release of cellular components that may affect neighboring tissue. In contrast, membrane rupture and release of cellular components during necrosis often leads to tissue inflammation.
  • Caspases are a family of serine proteases that are synthesized as inactive proenzymes. Their activation by apoptotic signals such as CD95 (Fas) death receptor activation or tumor necrosis factor results in the cleavage of specific target proteins and execution of the apoptotic program. Apoptosis may occur by either an extrinsic pathway involving the activation of cell surface death receptors (DR) or by an intrinsic mitochondrial pathway. Yoon, J-H. Gores G.J. (2002) Death receptor-mediated apoptosis and the liver. J. Hepatology 37:400-410. These pathways are not mutually exclusive and some cell types require the activation of both pathways for maximal apoptotic signaling.
  • DR cell surface death receptors
  • Hepatocytes are members of the Type-II cells in which mitochondria are essential for DR-mediated apoptosis
  • Bid is truncated by activated caspases-8/10 and translocates to the mitochondria.
  • DFF is composed of a 45 kDa regulatory subunit (DFF45) and a 40 kDA catalytic subunit (DFF40) .
  • DFF45 a 45 kDa regulatory subunit
  • DFF40 40 kDA catalytic subunit
  • Liu, X., Zou, H. , Slaughter, C Wang, X. (1997) DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis.
  • DFF45 cleavage by activated caspase-3 results in its dissociation from DFF40 and allows the caspase-activated DNAse (CAD) activity of DFF40 to cleave chromosomal DNA into oligonucleosomal size fragments.
  • CAD caspase-activated DNAse
  • CIDEs cell-death-inducing DFF45-like effectors
  • the CIDEs contain an N-terminal domain that shares homology with the N-terminal region of DFF45 and may represent a regulatory region via protein interaction. See Inohara, supra; Lugovskoy, A.A. , Zhou, P., Chou, J.J., McCarty, J.S., Li, P., Wagner, G. (1999) Solution structure of the CIDE-N domain of CIDE-B and a model for CIDE-N/CIDE-N interactions in the DNA fragmentation pathway of apoptosis. Cell 9:747- 755. The family members also share a C-terminal domain that is necessary and sufficient for inducing cell death and DNA fragmentation; see Inohara supra.
  • CIDE-A brown adipose tissue
  • BAT brown adipose tissue
  • CIDE-A can interact and inhibit UCP1 in BAT and may therefore play a role in regulating energy balance, see Zhou supra.
  • Previous reports have indicated that CIDE-A is not expressed in either adult human or mouse liver tissue, see Inohara supra, Zhou supra.
  • the human protein cell death activator CIDE-A is of particular interest because of its highly dramatic change in liver expression with age, first demonstrated in our Kopchick7 application, supra. CIDE-A expression is elevated in older normal mice.
  • CIDE-A expression was studied for normal C57BI/6J mouse ages 35, 49, 77, 133, 207, 403 and 558 days. Expression is low at the first five data points, then rises sharply at 403 days, and again at 558 days. CIDE-A was therefore classified as an "unfavorable protein", i.e., it was taught that an antagonist to CIDE-A could retard biological aging.
  • CIDE-A is also prematurely expressed in hyperinsulinemic and type-II diabetic mouse liver tissue. CIDE-A expression also correlates with liver steatosis in diet-induced obesity, hyperinsulinemia and type-II diabetes. These observations suggest an additional pathway of apoptotic cell death in Non-Alcoholic Fatty Liver Disease (NAFLD) and that CIDE-A may play a role in this serious disease and potentially in liver dysfunction associated with type-II diabetes.
  • NAFLD Non-Alcoholic Fatty Liver Disease
  • mice with a disrupted growth hormone receptor/binding protein gene enjoy an increased lifespan, as shown in the table below (17a) :
  • the 'connection may be direct (mouse cDNA to human protein) or indirect (e.g., mouse cDNA to mouse gene, mouse gene to human gene, human gene to human protein) .
  • mouse cDNA to mouse gene mouse gene to human gene, human gene to human protein
  • human genes/proteins which most closely correspond, directly or indirectly, to the mouse cDNA are preferred, such as the one(s) with the highest, top two highest, top three highest, top four highest, top five highest, and top ten highest E values for the final alignment in the connection process.
  • the human genes/proteins deemed to correspond to our mouse cDNA clones are identified in the Master Tables.
  • Agents which bind the "favorable" and “unf vorable” nucleic acids may be used to evaluate whether a human subject is at increased or decreased risk for faster-than-normal biological aging.
  • a subject with one or more elevated “unfavorable” and/or one or more depressed “favorable” genes/proteins is at increased risk, and one with one or more elevated “favorable” and/or one or more depressed “unfavorable” genes/proteins is at decreased risk.
  • the assay may be used as a preliminary screening assay to select subjects for further analysis, or as a formal diagnostic assay.
  • the identification of the related genes and proteins may also be useful in protecting humans against faster-than- normal or even normal aging (hereinafter, "the disorders") .
  • the related human DNAs may be identified by comparing the mouse sequence (or its AA translation product) to known human DNAs (and their AA translation products) . If this is unsuccessful, human cDNA or genomic DNA libraries may be screened using the mouse DNA as a probe. If there is no closely corresponding full-length mouse gene in the sequence databank, and the cDNA is not full- length, then the mouse cDNA may be used as a hybridization probe to screen a mouse cDNA library to isolate the corresponding full-length sequence. Alternatively, the mouse cDNA may be used as a probe to screen a mouse genomic DNA library.
  • infancy is defined as the period 0 to 21 days after birth. Sexual maturity is reached, on average, at 42 days after birth. The average lifespan is 832 days. In humans, infancy is defined as the period between birth and two years of age. Sexual maturity in males can occur between 9 and 14 years of age while the average age at first menstrual period for females is 12.6 years. The average human lifespan is 73 years for males and 79 years for females. The maximum verified human lifespan was 122 years, five months and 14 days.
  • aging per se to refer to "senescence”
  • maturation to refer to pre-maturation development.
  • mortality There is increased mortality with age after maturation.
  • rate of physiological decline varies from organ to organ and from individual to individual.
  • the physiological decline results in a reduced ability to respond adaptively to environmental stimuli, and increased susceptibility and vulnerability to disease.
  • Aging is the accumulation of diverse adverse changes that increase the risk of death. These changes can be attributed to development, genetic defects, the environment, disease , and the inborn aging process.
  • the chance of death at a given age serves as a measure of the number of accumulated changes, that is, of physiologic age, and the rate of change of this measure, as the rate of aging.”
  • the agents of the present invention inhibit aging for at least a subpopulation of mature (post-puberty) adult subjects.
  • health aging (sometimes called “successful aging”) refers to post-maturation changes in the body that occur with increasing age even in the absence of an overt disease.
  • increased age is a risk factor for many diseases (“age-related diseases”), and hence “total aging” includes both the basal effects of healthy aging and the effects of any age-related disease.
  • normal aging As a synonym for "healthy aging” , but a minority use it to refer to “total aging” . To minimize confusion, we will try to avoid the term “normal aging”, but if we use it, it is as a synonym for "healthy aging” .
  • Some scientists have suggested that normal aging changes should be defined as those which are universal, degenerative, progressive and intrinsic.
  • the agents of the present invention inhibit healthy aging for at least a subpopulation of mature (post- puberty) adult subjects. In both aging and senescence, many physiologic functions decline, but normal decline is not usually considered the same as disease. The distinction between normal decline and disease is often but not always clear and may be due only to statistical distribution.
  • Glucose intolerance is considered consistent with healthy aging, but diabetes is considered a disease, although a very common one.
  • Cognitive decline is nearly universal with advanced age and is considered healthy aging; however, cognitive decline consistent with dementia, although common in late life, is considered a disease (as in the case of Alzheimer's, a conclusion supported by analysis of brain tissue at autopsy) .
  • a decline in maximal heart rate is typical of healthy aging.
  • coronary heart disease is an age-related disease.
  • a decline in bone density is considered healthy aging, but when it drops to 2.5 SD below the young adult mean, it is called osteoporosis.
  • the changes typical of healthy aging are gradual, while those typical of a , disorder can be rapid.
  • the term average (median) "lifespan” is the chronological age to which 50% of a given population survive.
  • the maximum lifespan potential is the maximum age achievable by a member of the population. As a practical matter, it is estimated as the age reached by the longest lived member (or former member) of the population.
  • the (average) life expectancy is the number of remaining years that an individual of a given age can expect to live, based on the average remaining lifespans of a group of matched individuals.
  • the most widely accepted method of measuring the rate of aging is by reference to the average or the maximum lifespan. If a drug treatment achieves a statistically significant improvement in average or maximum lifespan in the treatment group over the control group, then it is inferred that the rate of aging was retarded in the treatment group.
  • the agents of the present invention have the effect of increasing the average lifespan and/or the maximum lifespan for at least a subpopulation of mature (post-puberty) adult subjects. This subpopulation may be defined by sex and/or age.
  • age 'then it may be defined by a minimum age (e.g., at least 30, at least 40, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 90, etc.) or by a maximum age (not more than 40, not more than 50, not more than 55, not more than 60, not more than 65, not more than 70, not more than 75, not more than 80, not more than 90, not more than 100, etc.), or by a rational combination of a minimum age and a maximum age so as to define a preferred close-ended age range, e.g., 55-75.
  • a minimum age e.g., at least 30, at least 40, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 90, etc.
  • a maximum age not more than 40, not more than 50, not more than 55, not more than 60, not more than 65, not more than 70, not more than 75
  • the subpopulation may additionally be defined by race, e.g., Caucasian, negroid or oriental, and/or by ethnic group, and/or by place of residence (e.g., North America, Europe) .
  • the subpopulation may additionally be defined by nonage risk factors for age-associated diseases, e.g., by blood pressure, body mass index, etc.
  • the subpopulation in which an agent of the present invention is reasonably expected to be effective is large, e.g., in the United States, preferably at least 100,000 individuals, more preferably at least 1,000,000 individuals, still more preferably at least 10,000,000, even more preferably at least 20,000,000, most preferably at least 40,000,000.
  • the U.S. population, by age was
  • biological age position in own life span (as fraction in range 0..1) X average life span for species.
  • a maximum lifespan study in mice can take 4-5 years.
  • a maximum lifespan study in dogs or cats would take 15-20 years, in monkeys, 30-40 years, and in humans, over 100 years. Even if the human study group were of sexagenarians, it would take 40-60 years to complete the study.
  • scientists have sought to identify biological markers (biomarkers) of biological aging, that is, characteristics that can be measured while the subjects are still alive, which correlate to lifespan. These biological markers can be used to calculate a "biological age" (syn.
  • Physiological age it is the chronological age at which an average member of the population (or relevant subpopulation) would have the same value of a biomarker of biological aging (or the same value of a composite measure of biomarkers of biological aging) as does the subject. This is the definition that will be used in this disclosure, unless otherwise stated.
  • the effect of aging varies from system to system, organ to organ, etc. For example, between ages 30 and 70 years, nerve conduction velocity decreases by only about 10%, but renal function decreases on average by nearly 40%. Thus, there isn't just one biological age for a subject.
  • biomarker By a suitable choice of biomarker, one may obtain a whole organism, or a system-, organ- or tissue-specific measure of biological aging, e.g., one can say that a person has the nervous system of a 30 year old but the renal system of a 60 year old. Biomarkers may measure changes at the molecular, cellular, tissue, organ, system or whole organism levels. Generally speaking, in the absence of some form of intervention (drugs, diet, exercise, etc.), biological ages will increase with time. The agents of the present invention preferably reduce the time rate of change of a biological age of the subject.
  • a biological age could refer to the overall biological age of the subject, to the biological age of a particular system, organ or tissue of that subject, or to some combination of the foregoing. More preferably, the agents of the present cannot only reduce the rate of increase of a biological age of the subject, but can actually reduce a biological age of the subj ect .
  • a simple biologic marker is a single biochemical, cellular, structural or functional indicator of an event in a biologic system or sample .
  • a composite biomarker is a mathematical combination of two or more simple biomarkers.
  • a superior biomarker of biological age would be a better predictor of lifespan than is chronological age (preferably for a chronological age at which 90% of the population is still alive) .
  • the biomarker preferably also satisfies one or more of the following desiderata: a statistically significant age- related change is apparent in humans after a period of at most a few years; not affected dramatically by physical conditioning (e.g., exercise), diet, and drug therapy (unless it is possible to discount these confounding influences, e.g., by reference to a second marker which measures them) ; can be tested repeatedly without harming the subject; works in lab animals as well as humans; simple and inexpensive to use; does not alter the result of subsequent tests for other biomarkers if it is to be used in conjunction with them; monitors a basic process that underlies the aging process, not the effects of disease.
  • biomarker works in lab animals, there is a statistically significant difference in the value of the biomarker between groups of food-restricted and normally-fed animals. It has been shown in some mammalian species that dietary restriction without malnutrition (e.g., caloric decrease of up to 40% from ad libitum feeding) increases lifespan.
  • a biomarker of aging may be used to predict, instead of lifespan, the "Healthy Active Life Expectancy" (HALE) or the "Quality Adjusted Life Years” (QALY) , or a similar measure which takes into account the quality of life before death as well as the time of death itself.
  • HALE Healthy Active Life Expectancy
  • QALY Quality Adjusted Life Years
  • a biomarker of aging may be used to predict, instead of lifespan, the timing and/or severity of a change in one or more age-related phenotypes as described below.
  • a biomarker of aging may be used to estimate, rather than overall biological age for a subject, a biological age for a specific body system or organ. The determination of the biological age of the liver, and the inhibition of biological aging of the liver, are of particular interest.
  • Body systems include the nervous system (including the brain, the sensory organs, and the sense receptors of the skin) , the cardiovascular system (includes the heart, the red blood cells and the reticuloendothelial system) , the respiratory system, the gastrointestinal system, the endocrine system (pituitary, thyroid, parathyroid and adrenal glands, gonads, pancreas, and parganglia) , the musculoskeletal system, the urinary system (kidneys, bladder, ureters, urethra) , the reproductive system and the immune system (bone marrow, thymus, lymph nodes, spleen, lymphoid tissue, white blood cells, and immunoglobulins) .
  • the nervous system including the brain, the sensory organs, and the sense receptors of the skin
  • the cardiovascular system includes the heart, the red blood cells and the reticuloendothelial system
  • the respiratory system the gastrointestinal system
  • the endocrine system pituitary
  • a biomarker may be useful in estimating the biological age of a system because the biomarker is a chemical produced by that system, because it is a chemical whose activity is primarily exerted within that system, because it is indicative of the morphological character or functional activity of that system, etc.
  • a given biomarker may be thus associated with more than one system.
  • a biomarker may be associated with the biological age, and hence the state, of a particular organ or tissue. The prediction of lifespan, or of duration of system or organ function at or above a particular desired level, may require knowledge of the value of at least one biomarker of aging at two or more times, adequately spaced, rather than of the value at a single time.
  • the levels (or changes in levels) of the human proteins identified in this specification, and their corresponding mRNAs may be used as simple biomarkers (direct or inverse) of biological aging. They may be used in conjunction with each other, or other simple biomarkers, in a composite biomarker.
  • a composite biomarker may be obtained by standard mathematical techniques, such as multiple regression, principal component analysis, cluster analysis, neural net analysis, and so forth.
  • the values may be standardized, e.g., by converting the raw scores into z-scores based on the distributions for each simple biomarker.
  • principal component analysis can be used to analyze the variation of lifespan with different observables, and the factor score coefficients from the first principal component can be used to derive an equation for estimating a biological age score. Nakamura, Exp Gerontol. 29(2):151-77 (1994). This approach was used to obtain the following BAS (for healthy Japanese women aged
  • BAS -4.37 -0.998FEV 1-0 +0.022SBP +0.133MCH +0.018GLU -1.505 A/G RATIO, where FEV 10 is the forced expiratory volume in 1 sec. (Liters), SBP is the systolic blood pressure (mm Hg) , MCH is the mean corpuscular hemoglobin (pg) , GLU is glucose (mg/dl) , and A/G RATIO is the ratio of albumin to globulin. The relative importance of these five biomarkers was 33.7%, 25.1%, 17.1%, 14.8% and 8.9%, respectively. Ueno, et al . , "Biomarkers of Aging in Women and the Rate of Longitudinal Changes," J. Physiol .
  • Biomarkers of aging are characteristics of an organism that correlate in large groups with chronological age and mortality. Of particular value in human applications are biomarkers of aging that also correlate with the quality of life in later life in the sense that they involve functions that are crucial to carrying out the activities of daily living.... A single biomarker of aging is limited by the fact that it measures only one isolated characteristic and is hardly representative of the diversity of functional and structural concomitants of aging....
  • Biological age, in contrast to chronological age, is an individual's hypothetical age calculated from scores obtained on a battery of tests of biomarkers of aging. As a first step in the calculation, the age of which each biomarker score is typical is determined by comparison with scores obtained by a large representative group of persons (or organisms) spanning a range of ages .
  • Abbo USP 6,547,729 teaches determining the biological age (he calls it "performance age") of a subject by (1) for a sample population, determining a regression curve relating some set of observed values for an "indicator” of the functionality of a bodily system to the chronological age of the observed individuals, (2) solving the regression equation to obtain a predicted performance age, given the value of the indicator for the subject.
  • the regression can be based on more than one indicator, i.e., it can be a multiple regression.
  • the sample population can be defined by sex, age range, ethnic composition, and geographic location.
  • the bodily system may be a molecular, cellular, tissue or organ system.
  • the following indicators are suggested by Abbo: nervous system (memory tests, reaction time, serial key tapping, digit recall test, letter fluency, category fluency, nerve conduction velocity) , arteries
  • endocrine glands load level of bioactive testosterone; level of dehydroepiandrosterone sulfate, ratio of urinary 17-ketosteroids/17- hydroxycorticosteroids; growth hormone; IGF-1) .
  • the agents of the invention have a favorable effect on the value of at least one simple biomarker of biological aging, such as any of the plausible biomarkers mentioned anywhere in this specification, other than the level of one of the proteins of the present invention. More preferably, they have a favorable effect on the value of at. least two such simple biomarkers of biological aging. Even more preferably, at least one such pair is of markers which are substantially non-correlated (R 2 ⁇ 0.5) .
  • the biomarkers in question reflect different levels of organization, and/or different body components at the same level of organization.
  • a visual reaction time with decision test is on the whole organism level, while a measurement of telomere length is on the cellular level .
  • a biomarker may, but need not, be an indicator related to one of the postulated causes or contributing factors of aging. It may, but need not, be an indicator of the acute health of a particular body system or organ.
  • a biomarker may measure behavior, cognitive or sensory function, or motor activity, or some combination thereof. It may measure the level of a type of cell (e.g., a T cell subset, such as CD4, CD4 memory, CD4 naive, and CD4 cells expressing P-glycoprotein) or of a particular molecule (e.g., growth hormone, IGF-1, insulin, DHEAS, an elongation factor, melatonin) or family of structurally or functionally related molecules in a particular body fluid (especially blood) or tissue. For example, lower serum IGF-1 levels are correlated with increasing age, and IGF-1 is produced by many different tissues. On the other hand, growth hormone is produced by the pituitary gland.
  • a biomarker may measure an indicator of stress
  • a biomarker may measure protein glycation or other protein modification (e.g., collagen crosslinking) . It has been theorized that such modifications contribute to aging.
  • the biomarker may measure changes in the lengths of telomeres or in the rate of cell division. It has been theorized that telomere shortening beyond a critical length leads the cell to stop proliferating. Average telomere length therefore provides a biomarker as to how may divisions the cell as previously undergone and how many divisions the cell can undergo in the future.
  • Suggested biomarkers have also included resting heart rate, resting blood pressure, exercise heart rate, percent body fat, flexibility, grip strength, push strength, abdominal strength, body temperature, and skin temperature.
  • the present invention does not require that all of the biomarkers identified above be validated as indicative of biological age, or that they be equally useful as measures of biological age.
  • An indicator of functional status is an indicator that defines a functional ability
  • An indicator of functional status may also be related to the increase in morbidity and mortality with chronological age.
  • Such indicators preferably predict physiological, cognitive and physical function in an age-coherent way, and do so better than chronological age. Preferably, they can predict the years of remaining functionality, and the trajectory toward organ-specific illness in the individual. Also, they are preferably minimally invasive. Suggested indicators include anthropometric data (body mass index, body composition, bone density, etc.), functional challenge tests (glucose tolerance, forced vital capacity) , physiological tests (cholesterol/HDL, glycosylated hemoglobin, homocysteine, etc.) and proteomic tests.
  • mice models for human aging exist. See Troen, supra, Table 3.
  • the drugs identified by the present invention may be further screened in one or more of these models.
  • Age-Related Phenotype An age-related phenotype is an observable change which occurs with age. An age-related phenotype may, but need not, also be a biomarker of biological aging.
  • the agent of the present invention favorably affects at least one age-related phenotype. More preferably, it favorably affects at least two age-related phenotypes, more preferably phenotypes of at least two different body systems.
  • the age-related phenotype may be a system level phenotype, such as a measure of the condition of the nervous system, respiratory system, immune system, circulatory system, endocrine system, reproductive system, gastrointestinal system, or musculoskeletal system.
  • the age-related phenotype may be an organ level phenotype, such as a measure of the condition of the brain, eyes, ears, lungs, spleen, heart, pancreas, liver, ovaries, testicles, thyroid, prostate, stomach, intestines, or kidney.
  • the age-related phenotype may be a tissue level phenotype, such as a measure of the condition of the muscle, skin, connective tissue, nerves, or bones.
  • the age-related phenotype may be a cellular level phenotype, such as a measure of the condition of the cell wall, mitochondria or chromosomes .
  • the age-related phenotype may be a molecular level phenotype, such as a measure of the condition of nucleic acids, lipids, proteins, oxidants, and anti-oxidants .
  • the age-related phenotype may be manifested in a biological fluid, such as blood, urine, saliva, lymphatic fluid or cerebrospinal fluid.
  • a biological fluid such as blood, urine, saliva, lymphatic fluid or cerebrospinal fluid.
  • the biochemical composition of these fluid may be an overall, system level, organ level, tissue level, etc. phenotype, depending on the specific biochemical and fluid involved.
  • the aging human liver appears to preserve its morphology and function relatively well.
  • the liver appears to progressively decrease in both mass and volume. It also appears browner (a condition called "brown atrophy"), as a result of accumulation of lipofuscin (ceroid) within hepatocytes .
  • Increases occur in the number of macrohepatocytes, and in polyploidy, especially around the terminal hepatic veins.
  • the number of mitochondria declines, and both the rough and smooth endoplasmic recticulum diminish.
  • the number of lysozymes increase.
  • the liver is the premiere metabolic organ of the body. With regard to metabolism, hepatic glycerides and cholesterol levels increase with age, at least up to age 90.
  • QOL quality of life
  • Clinicians are interested, not only in simple prolongation of lifespan, but also in maintenance of a high quality of life (QOL) over as much as possible of that lifespan.
  • QOL can be defined subjectively in terms of the subject's satisfaction with life, or objectively in terms of the subject's physical and mental ability (but not necessarily willingness) to engage in "valued activities" , such as those which are pleasurable or financially rewarding.
  • Flanagan has defined five domains of QOL, capturing 15 dimensions of life quality.
  • the five domains, and their component dimensions, are physical and material well being (Material well-being and financial security; Health and personal safety) , Relations with other people (relations with spouse; Having and rearing children; Relations with parents, siblings, or other relatives ; Relations with friends) Social, community, civic activities (Helping and encouraging others ,- Participating in local and governmental affairs ) , Personal development, fulfillment (Intellectual development;
  • Health-related quality of life is an individual's satisfaction or happiness with domains of life j-nsofar as they affect or are affected by "health” .
  • a pharmaceutical agent of the present invention is able to achieve a statistically significant improvement in the expected quality of life, measured according to a commonly accepted measure of QOL, in a treatment group over a control group.
  • QOL Quality of Life
  • Measurements of QOL can be objective (e.g., employment status, marital status, home ownership) or subjective (the subject's o oppiinniioonn ooff hhiiss oorr hher life), or some combination of the two .
  • a simple approach to measuring subjective QOL is to simply have the subjects rate their overall quality of life on a scale, e.g., of 7 points.
  • Objective QOL can be measured by, e.g., an activities checklist.
  • the Katz Index of Independence in Activities of Daily Living measures adequacy of independent performance of bathing, dressing, toileting, transferring, continence, and feeding. See Katz, S., "Assessing Self-Maintenance : Activities of Daily Living, Mobility and Instrumental Activities of Daily Living, Journal of the American
  • Performance of a more sophisticated nature is measured by the "Instrumental Activities of Daily Living” (IADL) scale. This inquires into ability to independently use the telephone, shop, prepare food, carry out housekeeping, do laundry, travel locally, take medication and handle finances. See Lawton, MP and Brody, EM, Gerontologist, 9:179-86 (1969) .
  • the 36 question Medical Outcomes Study Short Form (SF-36) (Medical Outcomes Trust, Inc., 20 Park Plaza, Suite 1014, Boston, Massachusetts 02116) assesses eight health concepts: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being) ; 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions.
  • SF-36 Medical Outcomes Study Short Form
  • a low score on an ADL, IADL or SF-36 test is likely to be associated with a low QOL, but a high score does not guarantee a high QOL because these tests do not explore performance of "valued activities" , only of more basic activities. Nonetheless, these tests can be considered commonly accepted measures of QOL for the purpose of this invention.
  • Age-related (senescent) diseases include certain cancers, atherosclerosis, diabetes (type 2) , osteoporosis, hypertension, depression, Alzheimer's, Parkinson's, glaucoma, certain immune system defects, kidney failure, and liver steatosis. In general, they are diseases for which the relative risk (comparing a subpopulation over age 55 to a suitably matched population under age 55) is at least 1.1.
  • the agents of the present invention protect against one or more age-related diseases for at least a subpopulation of mature (post-puberty) adult subjects.
  • Diabetes Type II diabetes is of particular interest. A deficiency of insulin in the body results in diabetes mellitus, which affects about 18 million individuals in the
  • diabetes mellitus There are two types of diabetes mellitus, Type I and
  • Type II diabetes is the predominant form found in the Western world; fewer than 8% of diabetic Americans have the type I disease.
  • Type I diabetes In Type I diabetes, formerly called juvenile-onset or insulin-dependent diabetes mellitus, the pancreas cannot produce insulin. People with Type I diabetes must have daily insulin injections. But they need to avoid taking too much insulin because that can lead to insulin shock, which begins with a mild hunger. This is quickly followed by sweating, shallow breathing, dizziness, palpitations, trembling, and mental confusion. As the blood sugar falls, the body tries to compensate by breaking down fat and protein to make more sugar. Eventually, low blood sugar leads to a decrease in the sugar supply to the brain, resulting in a loss of consciousness. Eating a sugary food can prevent insulin shock until appropriate medical measures can be taken.
  • Type I diabetics are often characterized by their low or absent levels of circulating endogenous insulin, i.e., hypoinsulinemia (1) .
  • Islet cell antibodies causing damage to the pancreas are frequently present at diagnosis. Injection of exogenous insulin is required to prevent ketosis and sustain life.
  • Type II diabetes formerly called adult-onset or non-insulin-dependent diabetes mellitus (NIDDM) , can occur at any age .
  • NIDDM non-insulin-dependent diabetes mellitus
  • Type II diabetes is a metabolic disorder that affects approximately 17 million Americans. It is estimated that another 10 million individuals are "prone" to becoming diabetic. These vulnerable individuals can become resistant to insulin, a pancreatic hormone that signals glucose (blood sugar) uptake by fat and muscle. In order to maintain normal glucose levels, the islet cells of the pancreas produce more insulin, resulting in a condition called hyperinsulinemia.
  • Type II diabetes is diagnosed.
  • Early Type II diabetics are often characterized by hyperinsulinemia and resistance to insulin.
  • Late Type II diabetics may be normoinsulinemic or hypoinsulinemic.
  • Type II diabetics are usually not insulin dependent or prone to ketosis under normal circumstances. i Little is known about the disease progression from the normoinsulinemic state to the hyperinsulinemic state, and from the hyperinsulinemic state to the Type II diabetic state.
  • type II diabetes is a metabolic disorder that is characterized by insulin resistance and impaired glucose-stimulated insulin secretion (2,3,4).
  • Type II diabetes and atherosclerotic disease are viewed as consequences of having the insulin resistance syndrome (IRS) for many years (5) .
  • the current theory of the pathogenesis of Type II diabetes is often referred to as the "insulin resistance/islet cell exhaustion" theory.
  • a condition causing insulin resistance compels the pancreatic islet cells to hypersecrete insulin in order to maintain glucose homeostasis.
  • the islet cells eventually fail and the symptoms of clinical diabetes are manifested. Therefore, this theory implies that, at some point, peripheral hyperinsulinemia will be an antecedent of Type II diabetes.
  • Peripheral hyperinsulinemia can be viewed as the difference between what is produced by the beta cell minus that which is taken up by the liver. Therefore, peripheral hyperinsulinemia can be caused by increased beta cell production, decreased hepatic uptake or some combination of both. It is also important to note that it is not possible to determine the origin of insulin resistance once it is established since the onset of peripheral hyperinsulinemia leads to a condition of global insulin resistance. Multiple environmental and genetic factors are involved in the development of insulin resistance, hyperinsulinemia and type II diabetes. An important risk factor for the development of insulin resistance, hyperinsulinemia and type
  • diabetes II diabetes is obesity, particularly visceral obesity
  • Type II diabetes exists world-wide, but in developed societies, the prevalence has risen as the average age of the population increases and the average individual becomes more obese .
  • genes/Proteins of Interest are those corresponding to genes less strongly expressed in longer lifespan (knockout mice) liver than in shorter lifespan (control mice) liver.
  • Unfavorable genes/proteins are those corresponding to genes more strongly expressed in control mice liver than in knockout mice liver.
  • Mixed genes/proteins are those exhibiting a combination of favorable and unfavorable behavior.
  • a mixed gene/protein can be used as would a favorable gene/protein if its favorable behavior outweighs the unfavorable. It can be used as would an unfavorable gene/protein if its unfavorable behavior outweighs the favorable .
  • they are used in conjunction with other agents that affect their balance of favorable and unfavorable behavior.
  • the cDNAs of the disclosed clones may be used directly. For diagnostic or screening purposes, they (or specific binding fragments thereof) may be labeled and used as hybridization probes. For therapeutic purposes, they (or specific binding fragments thereof) may be used as antisense reagents to inhibit the expression of the corresponding gene, or of a sufficiently homologous gene of another species . If the cDNA appears to be a full-length cDNA, that is, that it encodes an entire, functional protein, then it may be used in the expression of that protein.
  • Such expression may be in cell culture, with the protein subsequently isolated and administered exogenously to subjects who would benefit therefrom, or in vivo, i.e., administration by gene therapy.
  • any DNA encoding the same protein, or a fragment or a mutant protein which retains the desired activity may be used for the same purpose.
  • the encoded protein of course has utility therapeutically and, in labeled or immobilized form, diagnostically.
  • the cDNAs of the disclosed clones may also be used indirectly, that is, to identify other useful DNAs, proteins, or other molecules. We have attempted to determine whether the cDNAs disclosed herein have significant similarity to any known DNA, and whether, in any of the six possible combinations of reference frame and strand, they encode a protein similar to a known protein.
  • the known protein, and DNAs encoding that protein may be used in a similar manner.
  • the known protein is known to have additional homologues, then those homologous proteins, and DNAs encoding them, may be used in a similar manner.
  • a DNA->DNA (BlastN) search for database DNAs closely related to the mouse cDNA clone identifies a particular mouse (or other nonhuman, e.g., rat) gene, and that nonhuman gene encodes a protein for which there is a known human protein homologue;
  • a DNA->DNA (BlastN) search of the database for human DNAs closely related to the mouse cDNA clone identifies a particular human DNA as a homologue of the mouse cDNA, and the corresponding human protein is known (e.g., by translation of the human DNA) ;
  • mouse cDNA encodes a mouse protein which appears similar to a human protein
  • human protein may be used (especially in humans) for purposes analogous to the proposed use of the mouse protein in mice.
  • a specific binding fragment of an appropriate strand of the corresponding human gene or cDNA could be labeled and used as a hybridization probe (especially against samples of human mRNA or cDNA) .
  • AA sequences to known proteins one would generally use the disclosed cDNA as a query sequence in a search of a sequence database.
  • the results of several such searches are set forth in the Examples. Such results are dependent, to some degree, on the search parameters. Preferred parameters are set forth in Example 1.
  • the results are also dependent on the content of the database. While the raw similarity score of a particular target (database) sequence will not vary with content (as long as it remains in the database) , its informational value (in bits) , expected value, and relative ranking can change. Generally speaking, the changes are small . It is possible to use the sequence of the entire cDNA insert to query the database. However, the error rate increases as a sequencing run progresses.
  • the cognate DNAs and proteins include not only those set forth in the examples, but those which would have been highly ranked (top ten, more preferably top three, even more preferably top two, most preferably the top one) in a search run with the same parameters on the date of filing of this application.
  • the cDNA appears to be a partial cDNA, it may be used as a hybridization probe to isolate the full-length cDNA. If the partial cDNA encodes a biologically functional fragment of the cognate protein, it may be used in a manner similar to the full length cDNA, i.e., to produce the functional fragment.
  • an antagonist of a protein or other molecule may be obtained by preparing a combinatorial library, as described below, of potential antagonists, and screening the library members for binding to the protein or other molecule in question. The binding members may then be further screened for the ability to antagonize the biological activity of the target.
  • the antagonists may be used therapeutically, or, in suitably labeled or immobilized form, diagnostically. If the cDNA is related to a known protein, then substances known to interact with that protein (e.g., agonists, antagonists, substrates, receptors, second messengers, regulators, and so forth), and binding molecules which bind them, are also of utility. Such binding molecules can likewise be identified by screening a combinatorial library.
  • a cDNA of the present invention is a partial cDNA, and the cognate full length cDNA is not listed in a sequence database
  • the available cDNA may be used as a hybridization probe to isolate the full-length cDNA from a suitable cDNA library.
  • Stringent hybridization conditions are appropriate, that is, conditions in which the hybridization temperature is 5-10 deg. C. below the Tm of the cDNA as a perfect duplex.
  • sequence databases available do not include the sequence of any homologous gene, or at least of the homologous gene for a species of interest. However, given the cDNAs set forth above, one may readily obtain the homologous gene .
  • the possession of one cDNA greatly facilitates the isolation of homologous genes/cDNAs. If the clone in question only features a partial cDNA, this partial cDNA may first be used as a probe to isolate the corresponding full length cDNA for the same species, and that the latter may be used as the starting DNA in the search for homologous genes .
  • the starting DNA, or a fragment thereof is used as a hybridization probe to screen a cDNA or genomic DNA library for clones containing inserts which encode either the entire homologous protein, or a recognizable fragment thereof.
  • the human cDNA library is about 10 8 bases and the human genomic DNA library is about 10 10 bases.
  • the library is preferably derived from an organism which is known, on biochemical evidence, to produce a homologous protein, and more preferably from the genomic DNA or mRNA of cells of that organism which are likely to be relatively high producers of that protein.
  • a cDNA library (which is derived from an mRNA library) is especially preferred. If the organism in question is known to have substantially different codon preferences from that of the organism whose relevant cD ⁇ A or genomic D A is known, a synthetic hybridization probe may be used which encodes the same amino acid sequence but whose codon utilization is more similar to that of the D ⁇ A of the target organism.
  • the synthetic probe may employ inosine as a substitute for those bases which are most likely to be divergent, or the probe may be a mixed probe which mixes the codons for the source D ⁇ A with the preferred codons (encoding the same amino acid) for the target organism.
  • the Tm of a perfect duplex of starting DNA is determined. One may then select a hybridization temperature which is sufficiently lower than the perfect duplex Tm to allow hybridization of the starting DNA (or other probe) to a target DNA which is divergent from the starting DNA.
  • a 1% sequence divergence typically lowers the Tm of a duplex by 1-2°C, and the DNAs encoding homologous proteins of different species typically have sequence identities of around 50-80%.
  • the library is screened under conditions where the temperature is at least 20°C, more preferably at least 50°C, below the perfect duplex Tm. Since salt reduces the Tm, one ordinarily would carry out the search for DNAs encoding highly homologous proteins under relatively low salt hybridization conditions, e.g., ⁇ 1M NaCl. The higher the salt concentration, and/or the lower the temperature, the greater the sequence divergence which is tolerated.
  • salts to identify homologous genes in other species see, e.g., Schwinn, et al . , J. Biol. Chem., 265:8183-89 (1990) (hamster 67-bp cDNA probe vs.
  • human leukocyte genomic library human 0.32kb DNA probe vs. bovine brain cDNA library, both with hybridization at 42°C in 6xSSC) ; Jenkins et al . , J. Biol. Chem., 265:19624-31 (1990) (Chicken 770-bp cDNA probe vs. human genomic libraries; hybridization at 40°C in 50% formamide and 5xSSC) ; Murata et al., J. Exp. Med., 175:3,41-51 (1992) (1.2-kb mouse cDNA probe v. human eosinophil cDNA library; hybridization at 65°C in 6xSSC) ; Guyer et al . , J. Biol.
  • a human protein can be said to be identifiable as homologous to a mouse cDNA clone if (1) it can be aligned directly to the mouse cDNA clone by
  • BlastX genomic DNA
  • cDNA DNA complementary to messenger RNA
  • BlastP mouse protein by BlastP
  • BlastX mouse cDNA clone
  • BlastP it can be aligned to a mouse protein by BlastP, which in turn can be aligned to a mouse gene by BlastX, whose gDNA or cDNA can in turn be aligned to the mouse cDNA clone by BlastN;
  • any alignment by BlastN, BlastP, or BlastX is in accordance with the default parameters set forth below, and the expected value (E) of each alignment (the probability that such an alignment would have occurred by chance alone) is less than e-10.
  • a human gene is homologous to a mouse cDNA clone if it encodes a homologous human protein as defined above, or if it can be aligned either directly to the mouse cDNA clone, or indirectly through a mouse gene which can be aligned to said clone, according to the conditions set forth above.
  • two, three, four or all five of conditions (1) - (5) are satisfied.
  • for each of conditions (1) - (5) for at least the final alignment (i.e., vs.
  • the E value is less than e-15, more preferably less than e-20, still more preferably less than e-40, further more preferably less than e-50, even more preferably less than e- 60, considerably more preferably less than e-80, and most preferably less than e-100. More preferably, for those conditions in which the mouse cDNA clone is indirectly connected to the human protein by virtue of two or more successive alignments, the E value is so limited for all of said alignments in the connecting chain. BlastN and BlastX report very low expected values as
  • a human protein may be said to be functionally homologous to the mouse cDNA clone if (1) there is a mouse protein which is encoded by a mouse gene whose cDNA can be aligned to the mouse cDNA clone, using BlastX with the default parameters set forth below, and the E value of the alignment is less than e-50, and (2) the human protein has at least one biological activity in common with the mouse protein.
  • the human proteins of interest also include those that are substantially and/or conservatively identical (as defined below) to the homologous and/or functionally homologous human proteins defined above .
  • the complementary strand of the gene, or a portion thereof may be used in labeled form as a hybridization probe to detect messenger RNA and thereby monitor the level of expression of the gene in a subject. Elevated levels are indicative of progression, or propensity to progression, to a less favored state, and clinicians may take appropriate preventative, curative or ameliorative action.
  • the messenger RNA product (or equivalent cDNA) , the protein product, or a binding molecule specific for that product (e.g., an antibody which binds the product) , or a downstream product which mediates the activity (e.g., a signaling intermediate) or a binding molecule (e.g., an antibody) therefor, may be used, preferably in labeled or immobilized form, as an assay reagent in an assay for said nucleic acid product, protein product, or downstream product (e.g., a signaling intermediate) .
  • elevated levels are indicative of a present or future problem.
  • an agent which down-regul tes expression of the gene may be used to reduce levels of the corresponding protein and thereby inhibit further damage to the kidney.
  • This agent could inhibit transcription of the gene in the subject, or translation of the corresponding messenger RNA.
  • Possible inhibitors of transcription and translation include antisense molecules and repressor molecules.
  • the agent could also inhibit a post-translational modification (e.g., glycosylation, phosphorylation, cleavage, GPI attachment) required for activity, or post-translationally modify the protein so as to inactivate it.
  • a post-translational modification e.g., glycosylation, phosphorylation, cleavage, GPI attachment
  • it could be an agent which down- or up-regulated a positive or negative regulatory gene, respectively.
  • an agent which is an antagonist of the messenger RNA product or protein product of the gene, or of a downstream product through which its activity is manifested may be used to inhibit its activity.
  • This antagonist could be an antibody.
  • an agent which degrades, or abets the degradation of, that messenger RNA, its protein product or a downstream product which mediates its activity e.g., a signaling intermediate
  • the complementary strand of the gene, or a portion thereof may be used in labeled form as a hybridization probe to detect messenger RNA and thereby monitor the level of expression of the gene in a subject. Depressed levels are indicative of damage, or possibly of a propensity to damage, and clinicians may take appropriate preventative, curative or ameliorative action.
  • the messenger RNA product, the equivalent cDNA, protein product, or a binding molecule specific for those products, or a downstream product, or a signaling intermediate, or a binding molecule therefor may be used, preferably in labeled or immobilized form, as an assay reagent in an assay for said protein product or downstream product. Again, depressed levels are indicative of a present or future problem.
  • an agent which up-regulates expression of the gene may be used to increase levels of the corresponding protein and thereby inhibit further progression to a less favored state.
  • it could be a vector which carries a copy of the gene, but which expresses the gene at higher levels than does the endogenous expression system.
  • it could be an agent which up- or down-regulates a positive or negative regulatory gene.
  • an agent which is an agonist of the protein product of the gene, or of a downstream product through which its activity (of inhibition of progression to a less favored state) is manifested, or of a signaling intermediate may be used to foster its activity.
  • an agent which inhibits the degradation of that protein product or of a downstream product or of a signaling intermediate may be used to increase the effective period of activity of the protein.
  • Mutant Proteins The present invention also contemplates mutant proteins
  • a protein is more likely to tolerate a mutation which (a) is a substitution rather than an insertion or deletion; (b) is an insertion or deletion at the terminus, rather than internally, or, if internal, is at a domain boundary, or a loop or turn, rather than in an alpha helix or beta strand; (c) affects a surface residue rather than an interior residue; (d) affects a part of the molecule distal to the binding site; (e) is a substitution of one amino acid for another of similar size, charge, and/or hydrophobicity, and does not destroy a disulfide bond or other crosslink; and (f) is at a site which is subject to substantial variation among a family of homologous proteins to which the protein of interest belongs.
  • Binding Si te Residues forming the binding site may be identified by (1) comparing the effects of labeling the surface residues before and after complexing the protein to its target, (2) labeling the binding site directly with affinity ligands, (3) fragmenting the protein and testing the fragments for binding activity, and (4) systematic mutagenesis (e.g., alanine-scanning mutagenesis) to determine which mutants destroy binding. If the binding site of a homologous protein is known, the binding site may be postulated by analogy. Protein libraries may be constructed and screened that a large family (e.g., 10 8 ) of related mutants may be evaluated simultaneously. Hence, the mutations are preferably conservative modifications as defined below.
  • a mutant protein (peptide) is substantially identical to a reference protein (peptide) if (a) it has at least 10% of a specific binding activity or a non-nutritional biological activity of the reference protein, and (b) is at least 50% identical in amino acid sequence to the reference protein (peptide) . It is "substantially structurally identical” if condition (b) applies, regardless of (a) .
  • Percentage amino acid identity is determined by aligning the mutant and reference sequences according to a rigorous dynamic programming algorithm which globally aligns their sequences to maximize their similarity, the similarity being scored as the sum of scores for each aligned pair according to an unbiased PAM250 matrix, and a penalty for each internal gap of -12 for the first null of the gap and - 4 for each additional null of the same gap.
  • the percentage identity is the number of matches expressed as a percentage of the adjusted (i.e., counting inserted nulls) length of the reference sequence.
  • a mutant DNA sequence is substantially identical to a reference DNA sequence if they are structural sequences, and encoding mutant and reference proteins which are substantially identical as described above. If instead they are regulatory sequences, they are substantially identical if the mutant sequence has at least
  • the sequence is not merely substantially identical but rather is at least 51%, at least 66%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical in sequence to the reference sequence .
  • DNA sequences may also be considered "substantially identical" if they hybridize to each other under stringent conditions, i.e., conditions at which the Tm of the heteroduplex of the one strand of the mutant DNA and the more complementary strand of the reference DNA is not in excess of 10 °C. less than the Tm of the reference DNA homoduplex. Typically this will correspond to a percentage identity of 85-90%.
  • Constant Modifications are defined as ( (a) conservative substitutions of amino acids as hereafter defined; or (b) single or multiple insertions (extension) or deletions (truncation) of amino acids at the termini . Conservative modifications are preferred to other modifications. Conservative substitutions are preferred to other conservative modifications. "Semi-Conservative Modifications” are modifications which are not conservative, but which are (a) semi- conservative substitutions as hereafter defined; or (b) single or multiple insertions or deletions internally, but at interdomain boundaries, in loops or in other segments of relatively high mobility. Semi-conservative modifications are preferred to nonconservative modifications. Semi- conservative substitutions are preferred to other semi- conservative modifications.
  • Non-conservative substitutions are preferred to other non-conservative modifications.
  • the term "conservative" is used here in an a priori sense, i.e., modifications which would be expected to preserve 3D structure and activity, based on analysis of the naturally occurring families of homologous proteins and of past experience with the effects of deliberate mutagenesis, rather than post facto, a modification already known to conserve activity.
  • a modification which is conservative a priori may, and usually is, also conservative post facto.
  • no more than about five amino acids are inserted or deleted at a particular locus, and the modifications are outside regions known to contain binding sites important to activity.
  • insertions or deletions are limited to the termini .
  • a conservative substitution is a substitution of one amino acid for another of the same exchange group, the exchange groups being defined as follows I Gly, Pro, Ser, Ala (Cys) (and any nonbiogenic, neutral amino acid with a hydrophobicity not exceeding that of the aforementioned a.a.'s) II Arg, Lys, His (and any nonbiogenic, positively- charged amino acids) III Asp, Glu, Asn, Gin (and any nonbiogenic negatively-charged amino acids) IV Leu, lie, Met, Val (Cys) (and any nonbiogenic, aliphatic, neutral amino acid with a hydrophobicity too high for I above) V Phe, Trp, Tyr (and any nonbiogenic, aromatic neutral amino acid with a hydrophobicity too high for I above) .
  • Cys belongs to both I and IV. Residues Pro, Gly and Cys have special conformational roles. Cys participates in formation of disulfide bonds.
  • Gly imparts flexibility to the chain.
  • Pro imparts rigidity to the chain and disrupts ⁇ helices. These residues may be essential in certain regions of the polypeptide, but substitutable elsewhere. One, two or three conservative substitutions are more likely to be tolerated than a larger number. "Semi-conservative substitutions" are defined herein as being substitutions within supergroup I/II/III or within supergroup IV/V, but not within a single one of groups I-V.
  • Non-conservative substitutions are substitutions which are not “conservative” or “semi-conservative” .
  • “Highly conservative substitutions” are a subset of conservative substitutions, and are exchanges of amino acids within the groups Phe/Tyr/Trp, Met/Leu/lle/Val, His/Arg/Lys,
  • Asp/Glu and Ser/Thr/Ala are more likely to be tolerated than other conservative substitutions. Again, the smaller the number of substitutions, the more likely they are to be tolerated.
  • a protein (peptide) is conservatively identical to a reference protein (peptide) it differs from the latter, if at all, solely by conservative modifications, the protein (peptide remaining at least seven amino acids long if the reference protein (peptide) was at least seven amino acids long.
  • a protein is at least semi-conservatively identical to a reference protein (peptide) if it differs from the latter, if at all, solely by semi-conservative or conservative modifications .
  • a protein (peptide) is nearly conservatively identical to a reference protein (peptide) if it differs from the latter, if at all, solely by one or more conservative modifications and/or a single nonconservative substitution. It is highly conservatively identical if it differs, if at all, solely by highly conservative substitutions. Highly conservatively identical proteins are preferred to those merely conservatively identical. An absolutely identical protein is even more preferred.
  • the core sequence of a reference protein is the largest single fragment which retains at least 10% of a particular specific binding activity, if one is specified, or otherwise of at least one specific binding activity of the referent. If the referent has more than one specific binding activity, it may have more than one core sequence, and these may overlap or not . If it is taught that a peptide of the present invention may have a particular similarity relationship (e.g., markedly identical) to a reference protein (peptide) , preferred peptides are those which comprise a sequence having that relationship to a core sequence of the reference protein (peptide) , but with internal insertions or deletions in either sequence excluded. Even more preferred peptides are those whose entire sequence has that relationship, with the same exclusion, to a core sequence of that reference protein (peptide) .
  • Library generally refers to a collection of chemical or biological entities which are related in origin, structure, and/or function, and which can be screened simultaneously for a property of interest. Libraries may be classified by how they are constructed (natural vs. artificial diversity; combinatorial vs. noncombinatorial) , how they are screened (hybridization, expression, display) , or by the nature of the screened library members (peptides, nucleic acids, etc.) . In a "natural diversity” library, essentially all of the diversity arose without human intervention. This would be true, for example, of messenger RNA extracted from a non- engineered cell.
  • a limitation might be to cells of a particular individual, to a particular species, or to a particular genus, or, more complexly, to individuals of a particular species who are of a particular age, sex, physical condition, geographical location, occupation and/or familial relationship. Alternatively or additionally, it might be to cells of a particular tissue or organ. Or it could be cells exposed to particular pharmacological, environmental, or pathogenic conditions. Or the library could be of chemicals, or a particular class of chemicals, produced by such cells. In a "controlled structure" library, the library members are deliberately limited by the production conditions to particular chemical structures. For example, if they are oligomers, they may be limited in length and monomer composition, e.g. hexapeptides composed of the twenty genetically encoded amino acids.
  • hybridization Library In a hybridization library, the library members are nucleic acids, and are screened using a nucleic acid hybridization probe. Bound nucleic acids may then be amplified, cloned, and/or sequenced.
  • the screened library members are gene expression products, but one may also speak of an underlying library of genes encoding those products.
  • the library is made by subcloning DNA encoding the library members (or portions thereof) into expression vectors (or into cloning vectors which subsequently are used to construct expression vectors) , each vector comprising an expressible gene encoding a particular library member, introducing the expression vectors into suitable cells, and expressing the genes so the expression products are produced.
  • the expression products are secreted, so the library can be screened using an affinity reagent, such as an antibody or receptor.
  • the bound expression products may be sequenced directly, or their sequences inferred by, e.g., sequencing at least the variable portion of the encoding DNA.
  • the cells are lysed, thereby exposing the expression products, and the latter are screened with the affinity reagent.
  • the cells express the library members in such a manner that they are displayed on the surface of the cells, or on the surface of viral particles produced by the cells. (See display libraries, below) .
  • the screening is not for the ability of the expression product to bind to an affinity reagent, but rather for its ability to alter the phenotype of the host cell in a particular detectable manner.
  • the screened library members are transformed cells, but there is a first underlying library of expression products which mediate the behavior of the cells, and a second underlying library of genes which encode those products.
  • the library members are each conjugated to, and displayed upon, a support of some kind.
  • the support may be living (a cell or virus) , or nonliving
  • the support is a cell or virus
  • display will normally be effectuated by expressing a fusion protein which comprises the library member, a .carrier moiety allowing integration of the fusion protein into the surface of the cell or virus, and optionally a lining moiety.
  • the cell coexpresses a first fusion comprising the library member and a linking moiety LI, and a second fusion comprising a linking moiety L2 and the carrier moiety. LI and L2 interact to associate the first fusion with the second fusion and hence, indirectly, the library member with the surface of the cell or virus .
  • Soluble Library In a soluble library, the library members are free in solution.
  • a soluble library may be produced directly, or one may first make a display library and then release the library members from their supports.
  • Encapsulated Library In an encapsulated library, the library members are inside cells or liposomes. Generally speaking, encapsulated libraries are used to store the library members for future use; the members are extracted in some way for screening purposes. However, if they differentially affect the phenotype of the cells, they may be screened indirectly by screening the cells.
  • a cDNA library is usually prepared by extracting RNA from cells of particular origin, fractionating the RNA to isolate the messenger RNA (mRNA has a poly (A) tail, so this is usually done by oligo-dT affinity chromatography) , synthesizing complementary DNA (cDNA) using reverse transcriptase, DNA polymerase, and other enzymes, subcloning the cDNA into vectors, and introducing the vectors into ⁇ 61 cells. Often, only mRNAs or cDNAs of particular sizes will be used, to make it more likely that the cDNA encodes a functional polypeptide.
  • a cDNA library explores the natural diversity of the transcribed DNAs of cells from a particular source. It is not a combinatorial library.
  • a cDNA library may be used to make a hybridization library, or it may be used as an (or to make) expression 1ibrary.
  • Genomic DNA Library A genomic DNA library is made by extracting DNA from a particular source, fragmenting the DNA, isolating fragments of a particular size range, subcloning the DNA fragments into vectors, and introducing the vectors into cells. Like a cDNA library, a genomic DNA library is a natural diversity library, and not a combinatorial library. A genomic DNA library may be used the same way as a cDNA library.
  • Synthetic DNA library A synthetic DNA library may be screened directly (as a hybridization library) , or used in the creation of an expression or display library of peptides/proteins .
  • combinatorial libraries refers to a library in which the individual members are either systematic or random combinations of a limited set of basic elements, the properties of each member being dependent on the choice and location of the elements incorporated into it. Typically, the members of the library are at least capable of being screened simultaneously. Randomization may be complete or partial; some positions may be randomized and others predetermined, and at random positions, the choices may be limited in a predetermined manner.
  • the members of a combinatorial library may be oligomers or polymers of some kind, in which the variation occurs through the choice of monomeric building block at one or more positions of the oligomer or polymer, and possibly in terms of the connecting linkage, or the length of the oligomer or polymer, too.
  • the members may be nonoligomeric molecules with a standard core structure, like the 1, 4-benzodiazepine structure, with the variation being introduced by the choice of substituents at particular variable sites on the core structure.
  • the members may be nonoligomeric molecules assembled like a jigsaw puzzle, but wherein each piece has both one or more variable moieties (contributing to library diversity) and one or more constant moieties (providing the functionalities for coupling the piece in question to other pieces) .
  • each piece has both one or more variable moieties (contributing to library diversity) and one or more constant moieties (providing the functionalities for coupling the piece in question to other pieces) .
  • a “simple combinatorial library” is a mixture of two or more simple libraries, e.g., DNAs and peptides, or peptides, peptoids, and PNAs, or benzodiazepines and carbamates .
  • the number of component simple libraries in a composite library will, of course, normally be smaller than the average number of members in each simple library, as otherwise the advantage of a library over individual synthesis is small .
  • Libraries of thousands, even millions, of random oligopeptides have been prepared by chemical synthesis (Houghten et al .
  • the first combinatorial libraries were composed of peptides or proteins, in which all or selected amino acid positions were randomized. Peptides and proteins can exhibit high and specific binding activity, and can act as catalysts. In consequence, they are of great importance in biological systems. Nucleic acids have also been used in combinatorial libraries . Their great advantage is the ease with which a nucleic acid with appropriate binding activity can be amplified. As a result, combinatorial libraries composed of nucleic acids can be of low redundancy and hence, of high diversity.
  • the size of a library is the number of molecules in it.
  • the simple diversity of a library is the number of unique structures in it . There is no formal minimum or maximum diversity. If the library has a very low diversity, the library has little advantage over just synthesizing and screening the members individually. If the library is of very high diversity, it may be inconvenient to handle, at least without automatizing the process.
  • the simple diversity of a library is preferably at least 10, 10E2,
  • the simple diversity is usually not more than 10E15, and more usually not more than 10E10.
  • the average sampling level is the size divided by the simple diversity.
  • the expected average sampling level must be high enough to provide a reasonable assurance that, if a given structure were expected, as a consequence of the library design, to be present, that the actual average sampling level will be high enough so that the structure, if satisfying the screening criteria, will yield a positive result when the library is screened.
  • the preferred average sampling level is a function of the detection limit, which in turn is a function of the strength of the signal to be screened.
  • the library members may be presented as solutes in solution, or immobilized on some form of support.
  • the support may be living (cell, virus) or nonliving (bead, plate, etc.).
  • the supports may be separable (cells, virus particles, beads) so that binding and nonbinding members can be separated, or nonseparable (plate) .
  • the members will normally be placed on addressable positions on the support.
  • the advantage of a soluble library is that there is no carrier moiety that could interfere with the binding of the members to the support.
  • the advantage of an immobilized library is that it is easier to identify the structure of the members which were positive.
  • oligonucleotide libraries An oligonucleotide library is a combinatorial library, at least some of whose members are single-stranded oligonucleotides having three or more nucleotides connected by phosphodiester or analogous bonds.
  • the oligonucleotides may be linear, cyclic or branched, and may include non- nucleic acid moieties.
  • the nucleotides are not limited to the nucleotides normally found in DNA or RNA. For examples of nucleotides modified to increase nuclease resistance and chemical stability of aptamers, see Chart 1 in Osborne and Ellington, Chem. Rev., 97: 349-70 (1997).
  • RNA For screening of RNA, see Ellington and Szostak, Nature, 346: 818-22 (1990) . There is no formal minimum or maximum size for these oligonucleotides. However, the number of conformations which an oligonucleotide can assume increases exponentially with its length in bases. Hence, a longer oligonucleotide is more likely to be able to fold to adapt itself to a protein surface. On the other hand, while very long molecules can be synthesized and screened, unless they provide a much superior affinity to that of shorter molecules, they are not likely to be found in the selected population, for the reasons explained by Osborne and Ellington (1997) .
  • the libraries of the present invention are preferably composed of oligonucleotides having a length of 3 to 100 bases, more preferably 15 to 35 bases.
  • the oligonucleotides in a given library may be of the same or of different lengths.
  • Oligonucleotide libraries have the advantage that libraries of very high diversity (e.g., 10 15 ) are feasible, and binding molecules are readily amplified in vitro by polymerase chain reaction (PCR) .
  • PCR polymerase chain reaction
  • nucleic acid molecules can have very high specificity and affinity to targets.
  • this invention prepares and screens oligonucleotide libraries by the SELEX method, as described in King and Famulok, Molec. Biol. Repts . , 20: 97- 107 (1994) ; L. Gold, C. Tuerk. Methods of producing nucleic acid ligands, US#5595877; Oliphant et al . Gene 44:177
  • aptamer is conferred on those oligonucleotides which bind the target protein. Such aptamers may be used to characterize the target protein, both directly (through identification of the aptamer and the points of contact between the aptamer and the protein) and indirectly (by use of the aptamer as a ligand to modify the chemical reactivity of the protein) .
  • each nucleotide (monomeric unit) is composed of a phosphate group, a sugar moiety, and either a purine or a pyrimidine base.
  • DNA the sugar is deoxyribose and in RNA it is ribose .
  • the nucleotides are linked by 5 ' -3 ' phosphodiester bonds.
  • the deoxyribose phosphate backbone of DNA can be modified to increase resistance to nuclease and to increase penetration of cell membranes.
  • Derivatives such as mono- or dithiophosphates, methyl phosphonates, boranophosphates, formacetals, carbamates, siloxanes, and dimethylenethio- - sulfoxideo- and-sulfono- linked species are known in the art .
  • a peptide is composed of a plurality of amino acid residues joined together by peptidyl (-NHCO-) bonds.
  • a biogenic peptide is a peptide in which the residues are all genetically encoded amino acid residues; it is not necessary that the biogenic peptide actually be produced by gene expression.
  • Amino acids are the basic building blocks with which peptides and proteins are constructed. Amino acids possess both an amino group (-NH 2 ) and a carboxylic acid group (- COOH) . Many amino acids, but not all, have the alpha amino acid structure NH 2 -CHR-COOH, where R is hydrogen, or any of a variety of functional groups.
  • Twenty amino acids are genetically encoded: Alanine, Arginine, Asparagine, Aspartic Acid, Cysteine, Glutamic Acid, Glutamine, Glycine, Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Proline, Serine,
  • Threonine, Tryptophan, Tyrosine, and Valine are optically isomeric, however, only the L- form is found in humans. Nevertheless, the D-forms of these amino acids do have biological significance; D-Phe, for example, is a known analgesic.
  • Many other amino acids are also known, including: 2- Aminoadipic acid; 3-Aminoadipic acid; beta-Aminopropionic acid; 2-Aminobutyric acid; 4-Aminobutyric acid (Piperidinic acid) ; 6-Aminocaproic acid; 2-Aminoheptanoic acid; 2-
  • Aminoisobutyric acid 3-Aminoisobutyric acid; 2-Aminopimelic acid; 2 , 4-Diaminobutyric acid; Desmosine; 2,2'- Diaminopimelic acid; 2 , 3-Diaminopropionic acid; N- Ethylglycine; N-Ethylasparagine; Hydroxylysine; allo- Hydroxylysine; 3-Hydroxyproline; 4-Hydroxyproline;
  • Peptides are constructed by condensation of amino acids and/or smaller peptides.
  • the amino group of one amino acid (or peptide) reacts with the carboxylic acid group of a second amino acid (or peptide) to form a peptide (-NHCO-) bond, releasing one molecule of water. Therefore, when an amino acid is incorporated into a peptide, it should, technically speaking, be referred to as an amino acid residue.
  • the core of that residue is the moiety which excludes the -NH and -CO linking functionalities which connect it to other residues.
  • This moiety consists of one or more main chain atoms (see below) and the attached side chains.
  • the main chain moiety of each amino acid consists of the -NH and -CO linking functionalities and a core main chain moiety.
  • the core main chain moiety may include additional carbon atoms, and may also include nitrogen, oxygen or sulfur atoms, which together form a single chain.
  • the core main chain atoms consist solely of carbon atoms .
  • the side chains are attached to the core main chain atoms.
  • alpha amino acids in which the side chain is attached to the alpha carbon, the C-l, C-2 and N-2 of each residue form the repeating unit of the main chain, and the word "side chain” refers to the C-3 and higher numbered carbon atoms and their substituents. It also includes H atoms attached to the main chain atoms .
  • Amino acids may be classified according to the number of carbon atoms which appear in the main chain between the carbonyl carbon and amino nitrogen atoms which participate in the peptide bonds. Among the 150 or so amino acids which occur in nature, alpha, beta, gamma and delta amino acids are known. These have 1-4 intermediary carbons. Only alpha amino acids occur in proteins.
  • Proline is a special case of an alpha amino acid; its side chain also binds to the peptide bond nitrogen.
  • main chain core carbon a side chain other than H is attached to.
  • the preferred attachment site is the C-2 (alpha) carbon, i.e., the one adjacent to the carboxyl carbon of the -CO linking functionality.
  • more than one main chain atom to carry a side chain other than H.
  • only one main chain core atom carries a side chain other than H.
  • a main chain carbon atom may carry either one or two side chains; one is more common.
  • a side chain may be attached to a main chain carbon atom by a single or a double bond; the former is more common.
  • a simple combinatorial peptide library is one whose members are peptides having three or more amino acids connected via peptide bonds.
  • the peptides may be linear, branched, or cyclic, and may covalently or noncovalently include nonpeptidyl moieties.
  • the amino acids are not limited to the naturally occurring or to the genetically encoded amino acids.
  • a biased peptide library is one in which one or more (but not all) residues of the peptides are constant residues . Cyclic Peptides Many naturally occurring peptides are cyclic.
  • Cyclization is a common mechanism for stabilization of peptide conformation thereby achieving improved association of the peptide with its ligand and hence improved biological activity. Cyclization is usually achieved by intra-chain cystine formation, by formation of peptide bond between side chains or between N- and C- terminals. Cyclization was usually achieved by peptides in solution, but several publications have appeared that describe cyclization of peptides on beads .
  • a peptide library may be an oligopeptide library or a protein library.
  • the oligopeptides are at least five, six, seven or eight amino acids in length. Preferably, they are composed of less than 50, more preferably less than 20 amino acids . In the case of an oligopeptide library, all or just some of the residues may be variable.
  • the oligopeptide may be unconstrained, or constrained to a particular conformation by, e.g., the participation of constant cysteine residues in the formation of a constraining disulfide bond.
  • Proteins are composed of a plurality of amino acids, but the term protein is usually reserved for longer peptides, which are able to fold into a stable conformation.
  • a protein may be composed of two or more polypeptide chains, held together by covalent or noncovalent crosslinks. These may occur in a homooligomeric or a heterooligomeric state.
  • a peptide is considered a protein if it (1) is at least 50 amino acids long, or (2) has at least two stabilizing covalent crosslinks (e.g., disulfide bonds).
  • conotoxins are considered proteins .
  • the proteins of a protein library will be characterizable as having- both constant residues (the same for all proteins in the library) and variable residues
  • Surface residues may be determined by inspecting a 3D structure of the protein, or by labeling the surface and then ascertaining which residues have received labels. They may also be inferred by identifying regions of high hydrophilicity within the protein. Because proteins are often altered at some sites but not others, protein libraries can be considered a special case of the biased peptide library. There are several reasons that one might screen a protein library instead of an oligopeptide library, including (1) a particular protein, mutated in the library, has the desired activity to some degree already, and (2) the oligopeptides are not expected to have a sufficiently high affinity or specificity since they do not have a stable conformation.
  • the variable domains of an antibody possess hypervariable regions and hence, in some embodiments, the protein library comprises members which comprise a mutant of
  • VH or VL chain or a mutant of an antigen-specific binding fragment of such a chain.
  • VH and VL chains are usually each about 110 amino acid residues, and are held in proximity by a disulfide bond between the adjoing CL and CHI regions to form a variable domain. Together, the VH, VL, CL and CHI form an Fab fragment .
  • the hypervariable regions are at
  • VH and VL chains There is variation among VH and VL chains at residues outside the hypervariable regions, but to a much lesser degree .
  • a sequence is considered a mutant of a VH or VL chain if it is at least 80% identical to a naturally occurring VH or VL chain at all residues outside the hypervariable region.
  • such antibody library members comprise both at least one VH chain and at least one
  • VL chain at least one of which is a mutant chain, and which chains may be derived from the same or different antibodies.
  • VH and VL chains may be covalently joined by a suitable linker moiety, as in a "single chain antibody” , or they may be noncovalently joined, as in a naturally occurring variable domain. If the joining is noncovalent, and the library is displayed on cells or virus, then either the VH or the VL chain may be fused to the carrier surface/coat protein.
  • the complementary chain may be co-expressed, or added exogenously to the library.
  • the members may further comprise some or all of an antibody constant heavy and/or constant light chain, or a mutant thereof .
  • a peptoid is an analogue of a peptide in which one or more of the peptide bonds (-NH-CO-) are replaced by pseudopeptide bonds, which may be the same or different. It is not necessary that all of the peptide bonds be replaced, i.e., a peptoid may include one or more conventional amino acid residues, e.g., proline.
  • a peptide bond has two small divalent linker elements,
  • a preferred class of psuedopeptide bonds are those which consist of two small divalent linker elements.
  • Each may be chosen independently from the group consisting of amine (-NH-) , substituted amine (-NR-) , carbonyl (-CO-) , thiocarbonyl (-CS-) ,methylene (-CH2-) , monosubstituted methylene (-CHR-) , disubstituted methylene (-CR1R2-) , ether (-0-) and thioether (-S-) .
  • the more preferred pseudopeptide bonds include: N-modified -NRCO- Carba ⁇ -CH 2 -CH 2 - Depsi ⁇ -CO-0- Hydroxyethylene ⁇ -CHOH-CH 2 - Ketomethylene ⁇ -CO-CH 2 - Methylene-Oxy -CH 2 -0- Reduced -CH 2 -NH- Thiomethylene -CH 2 -S- Thiopeptide -CS-NH- Retro-Inverso -CO-NH-
  • a single peptoid molecule may include more than one kind of pseudopeptide bond.
  • the monomeric units which are not amino acid residues are of the structure -NR1-CR2-CO- , where at least one of Rl and R2 are not hydrogen. If there is variability in the pseudopeptide bond, this is most conveniently done by using an -NRCO- or other pseudopeptide bond with an R group, and varying the R group.
  • the R group will usually be any of the side chains characterizing the amino acids of peptides, as previously discussed. If the R group of the pseudopeptide bond is not variable, it will ⁇ usually be small, e.g., not more than 10 atoms (e.g., hydroxyl, amino, carboxyl, methyl, ethyl, propyl) . If the conjugation chemistries are compatible, a simple combinatorial library may include both peptides and peptoids .
  • PNA oligomer is here defined as one comprising a plurality of units, at least one of which is a PNA monomer which comprises a side chain comprising a nucleobase.
  • PNA monomer which comprises a side chain comprising a nucleobase.
  • the classic PNA oligomer is composed of (2- aminoethyl) glycine units, with nucleobases attached by methylene carbonyl linkers. That is, it has the structure
  • outer parenthesized substructure is the PNA monomer .
  • nucleobase B is separated from the backbone N by three bonds, and the points of attachment of the side chains are separated by six bonds.
  • the nucleobase may be any of the bases included in the nucleotides discussed in connection with oligonucleotide libraries.
  • the bases of nucleotides A, G, T, C and U are preferred.
  • a PNA oligomer may further comprise one or more amino acid residues, especially glycine and proline.
  • the small organic compound library (“compound library”, for short) is a combinatorial library whose members are suitable for use as drugs if, indeed, they have the ability to mediate a biological activity of the target protein.
  • Peptides have certain disadvantages as drugs. These include susceptibility to degradation by serum proteases, and difficulty in penetrating cell membranes. Preferably, all or most of the compounds of the compound library avoid, or at least do not suffer to the same degree, one or more of the pharmaceutical disadvantages of peptides. In designing a compound library, it is helpful to bear in mind the methods of molecular modification typically used to obtain new drugs.
  • disjunction in which a lead drug is simplified to identify its component pharmacophoric moieties
  • conj nction in which two or more known pharmacophoric moieties, which may be the same or different, are associated, covalently or noncovalently, to form a new drug
  • alteration in which one moiety is replaced by another which may be similar or different, but which is not in effect a disjunction or conjunction.
  • disjunction in which a lead drug is simplified to identify its component pharmacophoric moieties
  • conj nction in which two or more known pharmacophoric moieties, which may be the same or different, are associated, covalently or noncovalently, to form a new drug
  • alteration in which one moiety is replaced by another which may be similar or different, but which is not in effect a disjunction or conjunction.
  • Alterations include ring closing or opening, formation of lower or higher homologues, introduction or saturation of double bonds, introduction of optically active centers, introduction, removal or replacement of bulky groups, isosteric or bioisosteric substitution, changes in the position or orientation of a group, introduction of alkylating groups, and introduction, removal or replacement of groups with a view toward inhibiting or promoting inductive (electrostatic) or conjugative (resonance) effects.
  • the substituents may include electron acceptors and/or electron donors.
  • Typical electron donors (+1) include -CH 3 , -CH 2 R, -CHR 2 , -CR 3 and -COOA
  • the substituents may also include those which increase or decrease electronic density in conjugated systems.
  • the former (+R) groups include -CH 3 , -CR 3 , -F, -Cl, -Br, -I, -OH, -OR, -OCOR, -SH, -SR, -NH 2 , -NR 2 , and -NHCOR.
  • the later (-R) groups include -N0 2 , -CN, -CHC, -COR, -COOH, -COOR, -CONH 2 , -S0 2 R and -CF 3 . Synthetically speaking, the modifications may be achieved by a variety of unit processes, including nucleophilic and electrophilic substitution, reduction and oxidation, addition elimination, double bond cleavage, and cyclization.
  • a compound, or a family of compounds, having one or more pharmacological activities may be disjoined into two or more known or potential pharmacophoric moieties.
  • Analogues of each of these moieties may be identified, and mixtures of these analogues reacted so as to reassemble compounds which have some similarity to the original lead compound. It is not necessary that all members of the library possess moieties analogous to all of the moieties of the lead compound.
  • the design of a library may be illustrated by the example of the benzodiazepines .
  • benzodiazepine drugs including chlordiazepoxide, diazepam and oxazepam, have been used as anti-anxiety drugs.
  • Derivatives of benzodiazepines have widespread biological activities; derivatives have been reported to act not only as anxiolytics, but also as anticonvulsants; cholecystokinin (CCK) receptor subtype A or B, kappa opioid receptor, platelet activating factor, and HIV transactivator Tat antagonists, and GPIIblla, reverse transcriptase and ras farnesyltransferase inhibitors.
  • CCK cholecystokinin
  • the benzodiazepine structure has been disjoined into a 2-aminobenzophenone, an amino acid, and an alkylating agent. See Bunin, et al . , Proc. Nat. Acad. Sci. USA, 91:4708 (1994) . Since only a few 2-aminobenzophenone derivatives are commercially available, it was later disjoined into 2- aminoarylstannane, an acid chloride, an amino acid, and an alkylating agent. Bunin, et al . , Meth. Enzymol . , 267:448 (1996) .
  • the arylstannane may be considered the core structure upon which the other moieties are substituted, or all four may be considered equals which are conjoined to make each library member.
  • a basic library synthesis plan and member structure is shown in Figure 1 of Fowlkes, et al . , U.S. Serial No. 08/740,671, incorporated by reference in its entirety.
  • the acid chloride building block introduces variability at the R 1 site.
  • the R 2 site is introduced by the amino acid, and the R 3 site by the alkylating agent.
  • the R 4 site is inherent in the arylstannane. Bunin, et al .
  • variable elements included both aliphatic and aromatic groups.
  • aliphatic groups both acyclic and cyclic (mono- or poly-) structures, substituted or not, were tested. (although all of the acyclic groups were linear, it would have been feasible to introduce a branched aliphatic) .
  • aromatic groups featured either single and multiple rings, fused or not, substituted or not, and with heteroatoms or not.
  • Bunin et al suggest that instead of using a 1, 4- benzodiazepine as a core structure, one may instead use a 1, 4-benzodiazepine-2 , 5-dione structure. As noted by Bunin et al . , it is advantageous, although not necessary, to use a linkage strategy which leaves no trace of the linking functionality, as this permits construction of a more diverse library.
  • the hydantoins were synthesized by first simultaneously deprotecting and then treating each of five amino acid resins with each of eight isocyanates.
  • the benzodiazepines were synthesized by treating each of five deprotected amino acid resins with each of eight 2 -amino benzophenone imines . Chen, et al . , J. Am. Chem. Soc, 116:2661-62 (1994) described the preparation of a pilot (9 member) combinatorial library of formate esters.
  • a polymer bead- bound aldehyde preparation was "split" into three aliquots, each reacted with one of three different ylide reagents. The reaction products were combined, and then divided into three new aliquots, each of which was reacted with a different Michael donor. Compound identity was found to be determinable on a single bead basis by gas chromatography/mass spectroscopy analysis. Holmes, USP 5,549,974 (1996) sets forth methodologies for the combinatorial synthesis of libraries of thiazolidinones and metathiazanones . These libraries are made by combination of amines, carbonyl compounds, and thiols under cyclization conditions.
  • the library is preferably synthesized so that the individual members remain identifiable so that, if a member is shown to be active, it is not necessary to analyze it.
  • identification i.e., the attachment to each member of an identifier moiety which is more readily identified than the member proper. This has the disadvantage that the tag may itself influence the activity of the conjugate.
  • spatial addressing e.g., each member is synthesized only at a particular coordinate on or in a matrix, or in a particular chamber.
  • the present invention is not limited to any particular form of identification. However, it is possible to simply characterize those members of the library which are found to be active, based on the characteristic spectroscopic indicia of the various building blocks . Solid phase synthesis permits greater control over which derivatives are formed. However, the solid phase could interfere with activity. To overcome this problem, some or all of the molecules of each member could be liberated, after synthesis but before screening.
  • Examples of candidate simple libraries which might be evaluated include derivatives of the following: Cyclic Compounds Containing One Hetero Atom Heteronitrogen pyrroles pentasubstituted pyrroles pyrrolidines pyrrolines prolines indoles beta-carbolines pyridines dihydropyridines 1, 4-dihydropyridines pyrido [2 , 3 -d] pyrimidines tetrahydro-3H-imidazo [4, 5-c] pyridines Isoquinolines tetrahydroisoquinolines quinolones beta-lactams azabicyclo [4.3.0] nonen-8-one amino acid Heterooxygen furans tetrahydrofurans 2 , 5-disubstituted tetrahydrofurans pyrans hydroxypyranones tetrahydroxypyranones gamma-butyrolactones Heterosulfur sulfolenes Cyc
  • the preferred animal subject of the present invention is a mammal.
  • mammal an individual belonging to the class Mammalia.
  • the invention is particularly useful in the treatment of human subjects, although it is intended for veterinary and nutritional uses as well.
  • Preferred nonhuman subjects are of the orders
  • Primata e.g., apes and monkeys
  • Artiodactyla e.g., Artiodactyla
  • Perissodactyla e.g., cows, pigs, sheep, horses, goats
  • Carnivora e.g., cats, dogs
  • Rodenta e.g., rats, mice, guinea pigs, hamsters
  • Lagomorpha e.g., rabbits or other pet, farm or laboratory mammals.
  • protection is intended to include “prevention,” “suppression” and “treatment.”
  • Prevention strictly speaking, involves administration of the pharmaceutical prior to the induction of the disease (or other adverse clinical condition) .
  • Treatment involves administration of the composition prior to the clinical appearance of the disease.
  • Treatment involves administration of the protective composition after the appearance of the disease.
  • prevention will be understood to refer to both prevention in the strict sense, and to suppression.
  • the preventative or prophylactic use of a pharmaceutical involves identifying subjects who are at higher risk than the general population of contracting the disease, and administering the pharmaceutical to them in advance of the clinical appearance of the disease. The effectiveness of such use is measured by comparing the subsequent incidence or severity of the disease, or of particular symptoms of the disease, in the treated subjects against that in untreated subjects of the same high risk group .
  • a particular group e.g., a particular age, sex, race, ethnic group, etc.
  • a prophylaxis or treatment may be curative, that is, directed at the underlying cause of a disease, or ameliorative, that is, directed at the symptoms of the disease, especially those which reduce the quality of life. It should also be understood that to be useful, the protection provided need not be absolute, provided that it is sufficient to carry clinical value. An agent which provides protection to a lesser degree than do competitive agents may still be of value if the other agents are ineffective for a particular individual, if it can be used in combination with other agents to enhance the level of protection, or if it is safer than competitive agents.
  • At least one of the drugs of the present invention may be administered, by any means that achieve their intended purpose, to protect a subject against a disease or other adverse condition.
  • the form of administration may be systemic or topical.
  • administration of such a composition may be by various parenteral routes such as subcutaneous, intravenous, intradermal , intramuscular, intraperitoneal, intranasal, transdermal, or buccal routes.
  • parenteral routes such as subcutaneous, intravenous, intradermal , intramuscular, intraperitoneal, intranasal, transdermal, or buccal routes.
  • administration may be by the oral route.
  • Parenteral administration can be by bolus injection or by gradual perfusion over time.
  • a typical regimen comprises administration of an effective amount of the drug, administered over a period ranging from a single dose, to dosing over a period of hours, days, weeks, months, or years . It is understood that the suitable dosage of a drug of the present invention will be dependent upon the age, sex, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
  • the most preferred dosage can be tailored to the individual subject, as is understood and determinable by one of skill in the art, without undue experimentation. This will typically involve adjustment of a standard dose, e.g., reduction of the dose if the patient has a low body weight .
  • a drug Prior to use in humans, a drug will first be evaluated for safety and efficacy in laboratory animals. In human clinical studies, one would begin with a dose expected to be safe in humans, based on the preclinical data for the drug in question, and on customary doses for analogous drugs (if any) . If this dose is effective, the dosage may be decreased, to determine the minimum effective dose, if desired. If this dose is ineffective, it will be cautiously increased, with the patients monitored for signs of side effects.
  • the total dose required for each treatment may be administered by multiple doses or in a single dose.
  • the protein may be administered alone or in conjunction with other therapeutics directed to the disease or directed to other symptoms thereof .
  • the appropriate dosage form will depend on the disease, the pharmaceutical, and the mode of administration; possibilities include tablets, capsules, lozenges, dental pastes, suppositories, inhalants, solutions, ointments and parenteral depots.
  • the drug may be administered in the form of an expression vector comprising a nucleic acid encoding the peptide; such a vector, after incorporation into the genetic complement of a cell of the patient, directs synthesis of the peptide.
  • Suitable vectors include genetically engineered poxviruses (vaccinia) , adenoviruses, adeno-associated viruses, herpesviruses and lentiviruses which are or have been rendered nonpathogenic .
  • a pharmaceutical composition may contain suitable pharmaceutically acceptable carriers, such as excipients, carriers and/or auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. See, e.g., Berker, supra, Goodman, supra,
  • Target Organism The invention contemplates that it may be appropriate to ascertain or to mediate the biological activity of a substance of this invention in a target organism.
  • the target organism may be a plant, animal, or microorganism.
  • the drug may be intended to increase the disease, weather or pest resistance, alter the growth characteristics, or otherwise improve the useful characteristics or mute undesirable characteristics of the plant.
  • it may be a weed, in which case the drug may be intended to kill or otherwise inhibit the growth of the plant, or to alter its characteristics to convert it from a weed to an economic plant.
  • the plant may be a tree, shrub, crop, grass, etc.
  • the plant may be an algae (which are in some cases also microorganisms) , or a vascular plant, especially gymnosperms (particularly conifers) and angiosperms .
  • Angiosperms may be monocots or dicots.
  • the plants of greatest interest are rice, wheat, corn, alfalfa, soybeans, potatoes, peanuts, tomatoes, melons, apples, pears, plums, pineapples, fir, spruce, pine, cedar, and oak.
  • the target organism is a microorganism, it may be algae, bacteria, fungi, or a virus (although the biological activity of a virus must be determined in a virus-infected cell) .
  • the microorganism may be human or other animal or plant pathogen, or it may be nonpathogenic. It may be a soil or water organism, or one which normally lives inside other living things. If the target organism is an animal, it may be a vertebrate or a nonvertebrate animal. Nonvertebrate animals are chiefly of interest when they act as pathogens or parasites, and the drugs are intended to act as biocidic or biostatic agents. Nonvertebrate animals of interest include worms, mollusks, and arthropods. The target organism may also be a vertebrate animal, i.e., a mammal, bird, reptile, fish or amphibian.
  • the target animal preferably belongs to the order Primata (humans, apes and monkeys), Artiodactyla (e.g., cows, pigs, sheep, goats, horses), Rodenta (e.g., mice, rats) Lagomorpha (e.g., rabbits, hares), or Carnivora (e.g., cats, dogs) .
  • the target animals are preferably of the orders Anseriformes (e.g., ducks, geese, swans) or Galliformes (e.g., quails, grouse, pheasants, turkeys and chickens) .
  • target animal is preferably of the order Clupeiformes (e.g., sardines, shad, anchovies, whitefish, salmon) .
  • Target Tissues refers to any whole animal, physiological system, whole organ, part of organ, miscellaneous tissue, cell, or cell component (e.g., the cell membrane) of a target animal in which biological activity may be measured. Routinely in mammals one would choose to compare and -contrast the biological impact on virtually any and all tissues which express the subject receptor protein.
  • the main tissues to use are: brain, heart, lung, kidney, liver, pancreas, skin, intestines, adipose, stomach, skeletal muscle, adrenal glands, breast, prostate, vasculature, retina, cornea, thyroid gland, parathyroid glands, thymus, bone marrow, bone, etc.
  • Another classification would be by cell type: B cells,
  • T cells macrophages, neutrophils, eosinophils, mast cells, platelets, megakaryocytes, erythrocytes, bone marrow stomal cells, fibroblasts, neurons, astrocytes, neuroglia, microglia, epithelial cells (from any organ, e.g. skin, breast, prostate, lung, intestines etc) , cardiac muscle cells, smooth muscle cells, striated muscle cells, osteoblasts, osteocytes, chondroblasts, chondrocytes, keratinocytes, melanocytes, etc.
  • target organism and the "target tissue” .
  • Screening Assays intended to determine the binding or the biological activity of a substance are called preliminary screening assays .
  • Screening assays will typically be either in vitro (cell-free) assays (for binding to an immobilized receptor) or cell-based assays (for alterations in the phenotype of the cell) . They will not involve screening of whole multicellular organisms, or isolated organs. The comments on diagnostic biological assays apply mutatis mutandis to screening cell-based assays.
  • in vitro is descriptive of an event, such as binding or enzymatic action, which occurs within a living organism.
  • the organism in question may, however, be genetically modified.
  • the term in vi tro refers to an event which occurs outside a living organism. Parts of an organism (e.g., a membrane, or an isolated biochemical) are used, together with artificial substrates and/or conditions.
  • the term in vitro excludes events occurring inside or on an intact cell, whether of a unicellular or multicellular organism.
  • In vivo assays include both cell-based assays, and organismic assays.
  • the cell-based assays include both assays on unicellular organisms, and assays on isolated cells or cell cultures derived from multicellular organisms.
  • the cell cultures may be mixed, provided that they are not organized into tissues or organs.
  • organismic assay refers to assays on whole multicellular organisms, and assays on isolated organs or tissues of such organisms.
  • the in vitro assays of the present invention may be applied to any suitable analyte-containing sample, and may be qualitative or quantitative in nature.
  • sample will normally be a biological fluid, such as blood, urine, lymph, semen, milk, or cerebrospinal fluid, or a fraction or derivative thereof, or a biological tissue, in the form of, e.g., a tissue section or homogenate .
  • a biological fluid or tissue it may be taken from a human or other mammal, vertebrate or animal , or from a plant .
  • the preferred sample is blood, or a fraction or derivative thereof.
  • the assay may be a binding assay, in which one step involves the binding of a diagnostic reagent to the analyte, or a reaction assay, which involves the reaction of a reagent with the analyte.
  • the reagents used in a binding assay may be classified as to the nature of their interaction with analyte: (1) analyte analogues, or (2) analyte binding molecules (ABM) . They may be labeled or insolubilized.
  • the assay may look for a direct reaction between the analyte and a reagent which is reactive with the analyte, or if the analyte is an enzyme or enzyme inhibitor, for a reaction catalyzed or inhibited by the analyte.
  • the reagent may be a reactant, a catalyst, or an inhibitor for the reaction.
  • An assay may involve a cascade of steps in which the product of one step acts as the target for the next step.
  • These steps may be binding steps, reaction steps, or a combination thereof.
  • SPS Signal Producing System
  • the assay In order to detect the presence, or measure the amount, of an analyte, the assay must provide for a signal producing system (SPS) in which there is a detectable difference in the signal produced, depending on whether the analyte is present or absent (or, in a quantitative assay, on the amount of the analyte) .
  • SPS signal producing system
  • the detectable signal may be one which is visually detectable, or one detectable only with instruments. Possible signals include production of colored or luminescent products, alteration of the characteristics (including amplitude or polarization) of absorption or emission of radiation by an assay component or product, and precipitation or agglutination of a component or product.
  • signal is intended to include the discontinuance of an existing signal, or a change in the rate of change of an observable parameter, rather than a change in its absolute value.
  • the signal may be monitored manually or automatically.
  • the signal is often a product of the reaction.
  • a binding assay it is normally provided by a label borne by a labeled reagent .
  • a label may be, e.g., a radioisotope, a fluorophore, an enzyme, a co-enzyme, an enzyme substrate, an electron-dense compound, an agglutinable particle.
  • the radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or by autoradiography.
  • Isotopes which are particularly useful for the purpose of the present invention include 3 H, 125 I, 131 I , 35 S , 14 C , 32 P and 33 P . 125 I is preferred for antibody labeling .
  • the label may also be a fluorophore.
  • the fluorescently labeled reagent When the fluorescently labeled reagent is exposed to light of the proper wave length, its presence can then be detected due to fluorescence .
  • fluorescent labelling compounds are fluorescein .isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o- phthaldehyde and fluorescamine .
  • fluorescence-emitting metals such as 125 Eu, or others of the lanthanide series, may be incorporated into a diagnostic reagent using such metal chelating groups as diethylenetriaminepentaacetic acid (DTPA) ,of ethylenediamine-tetraacetic acid (EDTA) .
  • DTPA diethylenetriaminepentaacetic acid
  • EDTA ethylenediamine-tetraacetic acid
  • the label may also be a chemiluminescent compound. The presence of the chemilummescently labeled reagent is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction.
  • chemiluminescent labeling compounds examples include luminol, isolumino, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.
  • a bioluminescent compound may be used for labeling. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.
  • Enzyme labels such as horseradish peroxidase and alkaline phosphatase, are preferred.
  • the signal producing system must also include a substrate for the enzyme. If the enzymatic reaction product is not itself detectable, the SPS will include one or more additional reactants so that a detectable product appears.
  • An enzyme analyte may act as its own label if an enzyme inhibitor is used as a diagnostic reagent.
  • Binding assays may be divided into two basic types, heterogeneous and homogeneous.
  • heterogeneous assays the interaction between the affinity molecule and the analyte does not affect the label, hence, to determine the amount or presence of analyte, bound label must be separated from free label.
  • homogeneous assays the interaction does affect the activity of the label, and therefore analyte levels can be deduced without the need for a separation step.
  • the ABM is insolubilized by coupling it to a macromolecular support, and analyte in the sample is allowed to compete with a known quantity of a labeled or specifically labelable analyte analogue.
  • analyte analogue is a molecule capable of competing with analyte for binding to the ABM, and the term is intended to include analyte itself. It may be labeled already, or it may be labeled subsequently by specifically binding the label to a moiety differentiating the analyte analogue from analyte.
  • the solid and liquid phases are separated, and the labeled analyte analogue in one phase is quantified. The higher the level of analyte analogue in the solid phase, i.e., sticking to the ABM, the lower the level of analyte in the sample .
  • both an insolubilized ABM, and a labeled ABM are employed.
  • the analyte is captured by the insolubilized ABM and is tagged by the labeled ABM, forming a ternary complex.
  • the reagents may be added to the sample in either order, or simultaneously.
  • the ABMs may be the same or different.
  • the amount of labeled ABM in the ternary complex is directly proportional to the amount of analyte in the sample.
  • the two embodiments described above are both heterogeneous assays. However, homogeneous assays are conceivable. The key is that the label be affected by whether or not the complex is formed.
  • a label may be conjugated, directly or indirectly (e.g., through a labeled anti-ABM antibody), covalently (e.g., with SPDP) or noncovalently, to the ABM, to produce a diagnostic reagent.
  • the ABM may be conjugated to a solid phase support to form a solid phase ("capture") diagnostic reagent.
  • Suitable supports include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, agaroses, and magnetite.
  • the nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention.
  • the support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to its target.
  • the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod.
  • the surface may be flat such as a sheet, test strip, etc.
  • a biological assay measures or detects a biological response of a biological entity to a substance.
  • the biological entity may be a whole organism, an isolated organ or tissue, freshly isolated cells, an immortalized cell line, or a subcellular component (such as a membrane; this term should not be construed as including an isolated receptor) .
  • the entity may be, or may be derived from, an organism which occurs in nature, or which is modified in some way. Modifications may be genetic (including radiation and chemical mutants, and genetic engineering) or somatic (e.g., surgical, chemical, etc.). In the case of a multicellular entity, the modifications may affect some or all cells.
  • the entity need not be the target organism, or a derivative thereof, if there is a reasonable correlation between bioassay activity in the assay entity and biological activity in the target organism.
  • the entity is placed in a particular environment, which may be more or less natural.
  • a culture medium may, but need not, contain serum or serum substitutes, and it may, but need not, include a support matrix of some kind, it may be still, or agitated.
  • It may contain particular biological or chemical agents, or have particular physical parameters (e.g., temperature), that are intended to nourish or challenge the biological entity.
  • the direct signal produced by the biological marker may be transformed by a signal producing system into a different signal which is more observable, for example, a fluorescent or colorimetric signal .
  • the entity, environment, marker and signal producing system are chosen to achieve a clinically acceptable level of sensitivity, specificity and accuracy. In some cases, the goal will be to identify substances which mediate the biological activity of a natural biological entity, and the assay is carried out directly with that entity.
  • the biological entity is used simply as a model of some more complex (or otherwise inconvenient to work with) biological entity.
  • the model biological entity is used because activity in the model system is considered more predictive of activity in the ultimate natural biological entity than is simple binding activity in an in vitro system.
  • the model entity is used instead of the ultimate entity because the former is more expensive or slower to work with, or because ethical considerations forbid working with the ultimate entity yet .
  • the model entity may be naturally occurring, if the model entity usefully models the ultimate entity under some conditions. Or it may be non-naturally occurring, with modifications that increase its resemblance to the ultimate entity.
  • Transgenic animals such as transgenic mice, rats, and rabbits, have been found useful as model systems.
  • the receptor may be functionally connected to a signal (biological marker) producing system, which may be endogenous or exogenous to the cell .
  • “Zero-Hybrid” Systems In these systems, the binding of a peptide to the target protein results in a screenable or selectable phenotypic change, without resort to fusing the target protein (or a ligand binding moiety thereof) to an endogenous protein. It may be that the target protein is endogenous to the host cell, or is substantially identical to an endogenous receptor so that it can take advantage of the latter 's native signal transduction pathway. Or sufficient elements of the signal transduction pathway normally associated with the target protein may be engineered into the cell so that the cell signals binding to the target protein.
  • a chimera receptor a hybrid of the target protein and an endogenous receptor
  • the chimeric receptor has the ligand binding characteristics of the target protein and the signal transduction characteristics of the endogenous receptor.
  • the normal signal transduction pathway of the endogenous receptor is subverted.
  • the endogenous receptor is inactivated, or the conditions of the assay avoid activation of the endogenous receptor, to improve the signal-to-noise ratio. See Fowlkes USP 5,789,184 for a yeast system.
  • Another type of "one-hybrid” system combines a peptide: DNA-binding domain fusion with an unfused target receptor that possesses an activation domain.
  • the cell-based assay is a two hybrid system. This term implies that the ligand is incorporated into a first hybrid protein, and the receptor into a second hybrid protein.
  • the first hybrid also comprises component A of a signal generating system, and the second hybrid comprises component B of that system.
  • Components A and B by themselves, are insufficient to generate a signal. However, if the ligand binds the receptor, components A and B are brought into sufficiently close proximity so that they can cooperate to generate a signal .
  • Components A and B may naturally occur, or be substantially identical to moieties which naturally occur, as components of a single naturally occurring biomolecule, or they may naturally occur, or be substantially identical to moieties which naturally occur, as separate naturally occurring biomolecules which interact in nature.
  • two-Hybrid System Transcription Factor Type
  • one member of a peptide ligand: receptor binding pair is expressed as a fusion to a DNA-binding domain (DBD) from a transcription factor (this fusion protein is called the “bait"), and the other is expressed as a fusion to a transactivation domain (TAD) (this fusion protein is called the "fish", the "prey”, or the "catch”) .
  • the transactivation domain should be complementary to the DNA-binding domain, i.e., it should interact with the latter so as to activate transcription of a specially designed reporter gene that carries a binding site for the DNA-binding domain.
  • the two fusion proteins must likewise be complementary.
  • This complementarity may be achieved by use of the complementary and separable DNA-binding and transcriptional activator domains of a single transcriptional activator protein, or one may use complementary domains derived from different proteins.
  • the domains may be identical to the native domains, or mutants thereof.
  • the assay members may be fused directly to the DBD or TAD, or fused through an intermediated linker.
  • the target DNA operator may be the native operator sequence, or a mutant operator. Mutations in the operator may be coordinated with mutations in the DBD and the TAD.
  • a suitable transcription activation system is one comprising the DNA-binding domain from the bacterial repressor LexA and the activation domain from the yeast transcription factor Gal4, with the reporter gene operably linked to the LexA operator. It is not necessary to employ the intact target receptor; just the ligand-binding moiety is sufficient.
  • the two fusion proteins may be expressed from the same ( or different vectors.
  • the activatable reporter gene may be expressed from the same vector as either fusion protein (or both proteins) , or from a third vector.
  • Potential DNA-binding domains include Gal4, LexA, and mutant domains substantially identical to the above.
  • Potential activation domains include E. coli B42, Gal4 activation domain II, and HSV VP16, and mutant domains substantially identical to the above.
  • the assay system will include a signal producing system, too.
  • the first element of this system is a reporter gene operably linked to an operator responsive to the DBD and TAD of choice. The expression of this reporter gene will result, directly or indirectly, in a selectable or screenable phenotype (the signal) .
  • the signal producing system may include, besides the reporter gene, additional genetic or biochemical elements which cooperate in the production of the signal. Such an element could be, for example, a selective agent in the cell growth medium.
  • the sensitivity of the system may be adjusted by, e.g., use of competitive inhibitors of any step in the activation or signal production process, increasing or decreasing the number of operators, using a stronger or weaker DBD or TAD, etc .
  • the assay is said to be a selection.
  • the signal merely results in a detectable phenotype by which the signaling cell may be differentiated from the same cell in a nonsignaling state (either way being a living cell)
  • the assay is a screen.
  • the term "screening assay” may be used in a broader sense to include a selection.
  • nonselective screen When the narrower sense is intended, we will use the term "nonselective screen” .
  • Screening and selection may be for or against the peptide: target protein or compound: target protein interaction.
  • Preferred assay cells are microbial (bacterial, yeast, algal, protozooal) , invertebrate, vertebrate (esp. mammalian, particularly human) .
  • the best developed two- hybrid assays are yeast and mammalian systems. Normally, two hybrid assays are used to determine whether a protein X and a protein Y interact, by virtue of their ability to reconstitute the interaction of the DBD and the TAD.
  • reporter Enzyme type In another embodiment, the components A and B reconstitute an enzyme which is not a transcription factor.
  • the effect of the reconstitution of the enzyme is a phenotypic change which may be a screenable change, a selectable change, or both.
  • Radio-labeled ABM may be administered to the human or animal subject. Administration is typically by injection, e.g., intravenous or arterial or other means of administration in a quantity sufficient to permit subsequent dynamic and/or static imaging using suitable radio-detecting devices.
  • the dosage is the smallest amount capable of providing a diagnostically effective image, and may be determined by means conventional in the art, using known radio-imaging agents as a guide. Typically, the imaging is carried out on the whole body of the subject, or on that portion of the body or organ relevant to the condition or disease under study. The amount of radio-labeled ABM accumulated at a given point in time in relevant target organs can then be quantified.
  • a particularly suitable radio-detecting device is a scintillation camera, such as a gamma camera.
  • a scintillation camera is a stationary device that can be used to image distribution of radio-labeled ABM.
  • the detection device in the camera senses the radioactive decay, the distribution of which can be recorded.
  • Data produced by the imaging system can be digitized.
  • the digitized information can be analyzed over time discontinuously or continuously.
  • the digitized data can be processed to produce images, called frames, of the pattern of• uptake of the radio- labelled ABM in the target organ at a discrete point in time. In most continuous (dynamic) studies, quantitative data is obtained by observing changes in distributions of radioactive decay in target organs over time.
  • a time-activity analysis of the data will illustrate uptake through clearance of the radio-labeled binding protein by the target organs with time.
  • the radioisotope must be selected with a view to obtaining good quality resolution upon imaging, should be safe for diagnostic use in humans and animals, and should preferably have a short physical half-life so as to decrease the amount of radiation received by the body.
  • the radioisotope used should preferably be pharmacologically inert, and, in the quantities administered, should not have any substantial physiological effect.
  • the ABM may be radio-labeled with different isotopes of iodine, for example 123 I, 15 I, or 131 I (see for example, U.S. Patent 4,609,725).
  • the extent of radio-labeling must, however be monitored, since it will affect the calculations made based on the imaging results (i.e. a diiodinated ABM will result in twice the radiation count of a similar monoiodinated ABM over the same time frame) .
  • radioisotopes other than 125 I for labeling in order to decrease the total dosimetry exposure of the human body and to optimize the detectability of the labeled molecule (though this radioisotope can be used if circumstances require) . Ready availability for clinical use is also a factor. Accordingly, for human applications, preferred radio-labels are for example, 99m Tc, 67 Ga, 68 Ga, 90 Y, 1:L1 In, 113m ln, 123 I, 18S Re, 188 Re or 211 At .
  • the radio-labelled ABM may be prepared by various methods.
  • radio-halogenation by the chloramine - T method or the lactoperoxidase method and subsequent purification by HPLC (high pressure liquid chromatography) , for example as described by J. Gutkowska et al in "Endocrinology and Metabolism Clinics of America: (1987) 16 (1) :183.
  • HPLC high pressure liquid chromatography
  • IODOBEADSTM IODOBEADSTM
  • parenteral administration i.e., intravenous, subcutaneous, intramuscular
  • ABM an antibody
  • mice significantly shortens lifespan (Doi et al . , 1988).
  • the objective of this study was to examine gene expression differences between livers of GHR/BP -/- and +/+ mice in an attempt to account for some of the physiological changes and to identify cDNAs that are regulated by GH signaling.
  • mice 60 day old male growth hormone receptor/binding protein gene disrupted (GHR-BP -/-) mice and their respective controls in a BalbC/129 Ola genetic background were sacrificed and total liver RNA was isolated.
  • GHR-BP -/- mice 60 day old male growth hormone receptor/binding protein gene disrupted mice and their respective controls in a BalbC/129 Ola genetic background were sacrificed and total liver RNA was isolated.
  • Table A Summary of physiological alterations of GHR/BP -/ ⁇ mice .
  • RNA isolation For identification of differentially expressed genes, total RNA was isolated from the livers of 60 day old male GHR/BP -/- mice and +/+ controls using the RNA STAT-60 Total RNA/mRNA Isolation Reagent according to the manufacturer's instructions (Tel-Test, Friendswood, TX) . For further characterization of the identified genes, expression in mice of other ages, in female mice, in other tissues, and in other mouse models, was considered as described below.
  • RNA synthesis for subtraction library Prior to cDNA synthesis, a portion (50 ⁇ g) of RNA was further purified to remove small RNAs using the RNeasy Mini protocol for RNA clean up as instructed by the manufacturer (Qiagen Inc., Santa Clarita, CA) .
  • the cDNA was synthesized using 1 ⁇ g of total RNA from GHR/BP -/- and wildtype control mice using the SMART PCR cDNA Synthesis Kit according to the manufacturer's instructions (CLONTECH, Palo Alto, CA) .
  • Differential Screening kit Potential differentially expressed clones were selected based on difference in signal between the two blots upon exposure to autoradiography film.
  • Nucleotide sequence determination Plasmid DNA from bacterial colonies carrying the differentially expressed cDNA inserts was isolated using the QIAprep Spin Miniprep Kit according to the manufacturer's instructions (Qiagen Inc., Santa Clarita, CA) . Nucleotide sequences were determined by use of the ABI PRISM BigDye Terminator Cycle
  • RNA (5-15 ug) isolated from GHR/BP -/- orwild-type control mice was resolved by agarose gel electrophoresis through a 1% agarose, 1 % formaldehyde denaturing gel, transferred to positively charged nylon membrane, and hybridized to a probe labeled with [32P] dCTP that was generated from the cDNA insert using the Random Primed DNA Labeling Kit (Roche, Palo Alto, CA) , or to an asymmetric PCR amplified, digoxigenin (DIG) labeled probe synthesized from each clone of interest. In the latter case, blots were hybridized in DIG EasyHybe (Roche) and detection was performed following the manufacturer's guidelines (The DIG System User's Guide for Filter Hybridization, Roche) .
  • Nucleotide sequences were displayed using ABI prism Edit View 1.0.1 (PE Applied Biosystems, Foster City, CA) or Vector NT 6.0 (Informax) .
  • Nucleotide database searches were conducted with the then current version of BLASTN 2.0.12, see Altschul, et al . , "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res., 25:3389-3402 (1997) . Searches employed the default parameters, unless otherwise stated. For blastN searches, the default was the blastN matrix (1,-3), with gap penalties of 5 for existence and 2 for extension.
  • Protein database searches were conducted with the then- current version of BLAST X, see Altschul et al . (1997), supra . Searches employed the default parameters, unless otherwise stated.
  • the scoring matrix was BLOSUM62, with gap costs of 11 for existence and 1 for extension.
  • the standard low complexity filter was used.
  • "ref” indicates that NCBI's RefSeq is the source database.
  • the identifier that follows is a RefSeq accession number, not a GenBank accession number.
  • RefSeq sequences are derived from GenBank and provide non-redundant curated data representing our current knowledge of known genes. Some records include additional sequence information that was never submitted to an archival database but is available in the literature.
  • the cDNA library was screened using previously isolated partial fragments obtained from the PCR-Select cDNA Subtraction Kit (Clontech, Palo Alto, CA) and labeled with DIG using asymmetric PCR as described for Northern blot analysis.
  • Rapid Amplification of cDNA Ends was performed with the following primers in pursuit of the full-length clones for 5-9 and 5-61.
  • RNA for the RACE reactions was isolated from a 60 day old GHR/BP homozygous knockout male mouse using the RNA Stat-60 reagent and protocol (Tel-Test, Friendswood, TX) .
  • RACE was performed as per protocol using the 5'/3' RACE Kit, 2 nd Generation (Roche Applied Science, Penzberg, Germany) . Annealing temperatures used for the 5-9 primers were 55 degrees Celsius and for the 5-61 primers were 65 degrees Celsius.
  • Clone 5-43 The sequence for Clone 5-43 was derived entirely from the clone obtained from the cDNA library. The full-length clone 5-43 was obtained by screening the cDNA library using a partial fragment corresponding to nucleotides 481 through 1068.
  • Clone 5-61 The sequence for Clone 5-61 was derived from a cDNA clone followed by 5' RACE. The cDNA clone was obtained by screening a cDNA library using a partial fragment corresponding to nucleotides 838 through 1377 that was previously isolated from a cDNA subtraction library. Clone 5-9.
  • the sequence for Clone 5-9 was derived from a partial cDNA clone followed by 5 'RACE.
  • the partial cDNA clone was obtained by differential hybridization of two cDNA subtraction libraries as described in the Methods section. Results Of 192 total clones screened, ten clones appear to be differentially expressed, of which three are novel. The latter show increased expression in the livers of GHR/BP -/- mice . Each of these clones appears to be regulated in a unique fashion, thus they represent diverse gene regulation events that occur as a consequence of disrupted GH signaling.
  • RNA was isolated from 60 day old male liver, kidney, muscle, heart, lung, spleen, brain, white adipose tissue (WAT) , testis, intestine, stomach, and pancreas tissues. Clone 5-43 mRNA expression was detected at highest levels in liver, lung, WAT, intestine and stomach of both GHR/BP +/+ and -/- mice. Expression of the smaller transcript of clone 5-9 mRNA is seen only in the livers of
  • GHR/BP +/+ and -/- mice whereas the larger transcript is expressed in the liver, kidney and WAT of GHR/BP -/- mice.
  • mRNA expression of clone 5-61 was limited to tissues of GHR/BP -/- mice with greatest expression detected in liver, kidney and WAT.
  • RNA expression as a function of age Total RNA was isolated from livers of 2 , 5, 12 and 24 month old female GHR/BP -/- and +/+ mice. Liver RNA was also isolated from these mice toward the end of their lifespan: 30 months for GHR/BP +/+ and 36 months for -/- mice. Hybridization was with each respective clone as probe. Clone 5-43 mRNA expression was detected in all samples of both GHR/BP +/+ and -/- mice. The smaller transcript for clone 5-9 mRNA was expressed in all samples of both GHR/BP +/+ and -/- mice while expression of the larger transcript was only apparent in the GHR/BP -/- mice. mRNA expression of clone 5-61 was detected throughout the lifespan of GHR/BP -/- mice and was not detected at any time point in +/+ mice. No significant age-dependent regulation of expression was evident for any of these clones.
  • Clone 5-43 mRNA is expressed in the liver of all three mouse models tested, in all tissues tested, as well as all non-transgenic controls. Highest expression was seen in the liver, kidney, intestine and brain. Clone 5-43 mRNA appears to be up-regulated in the livers of GHR/BP -/- males compared to controls. This up-regulation was not observed in GHR/BP -/- females. Also, Clone 5-9 mRNA expression was seen in the liver of all three mouse models tested as well as all controls. A second larger transcript was detected in the GHR/BP -/- liver but was not present in other mouse models or controls.
  • daf- 16 an HNF-3/Forkhead family member that can function to double the life-span of Caenorhabdi tis elegans . Science 278, 1319-1322.
  • mice Bartke A, Wright JC, Mattison JA, Ingram DK, Miller RA, Roth GS . (2001) Extending the lifespan of long-lived mice.
  • Ci tation of documents herein is not intended as an admission that any of the documents ci ted herein is pertinent prior art, or an admission that the ci ted documents is considered material to the patentabili ty of any of the claims of the present application . All statements as to the date or representation as to the contents of these documents is based on the information available to the applicant and does not consti tute any admission as to the correctness of the dates or contents of these documents .
  • the appended claims are to be treated as a non-limi ting reci tation of preferred embodiments .
  • 4-29 is not full length but it is matching with a portion of the mitochondrial genome, specifically the 16s ribosomal RNA. There is no corresponding protein match for this reason.
  • 4-130 is not full length but the mouse and human protein homologs are.
  • 5-105 is not full length but the mouse homolog is and the potential human protein homolog is not.
  • 5-38 is full length.
  • the potential human homolog is not full length.
  • 5-41 is not full length but the mouse and human homologs are. *The human and mouse protein homologs are listed by inference since the 5-41 sequence is predominantly in the 3' non-coding region.
  • 5-43 is a novel 1542 bp full length cDNA isolated from a GHR/BP -/- liver cDNA library. This cDNA encodes a 247 amino acid protein of unknown function.
  • 5-61 is a novel partial clone.
  • 5-9 is a novel clone.
  • Clone 5-9 shows two different sized transcripts via Northern analysis. The larger transcript only shows up in the GHR/BP -/- mice. The databases show several mRNA sequences that increase in size, all at the 5' end.
  • the 2766 bp mRNA BC030852 is used here as a reference for nucleotide numbers.
  • Our original clone fragment matches the nucleotide sequence of BC030852 from 2367 to 2683.
  • 5-138 is full length.
  • the potential human homolog is not full length.
  • Col. 5 The E value for the alignment of the query sequence set forth in col. 6 to the human protein set forth in col . 4. There is one entry for each human protein in col . 4. Col. 6. The database accession number of the corresponding human gene. There is one entry for each human protein in col. 4.
  • 5-41 Clone nucleotide sequence is 3' of human CDS. (human protein and e-value is from Blastn)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention se rapporte à l'expression différentielle des gènes de souris lors de comparaisons de l'expression dans les foies de souris porteuses d'une disruption du gène de la protéine de liaison récepteur/hormone de croissance et dans les foies de souris normales, ainsi qu'à l'identification des protéines et gènes correspondants chez l'homme. Les molécules humaines, ou les antagonistes de celle-ci peuvent être utilisées pour la protection contre un vieillissement biologique plus rapide que la normale, ou pour produire un vieillissement retardé par rapport à la normale. Les molécules humaines peuvent également servir de marqueurs du vieillissement biologique, ou être utilisées pour retarder le vieillissement biologique ou pour traiter les pathologies liées à l'âge.
PCT/US2004/021944 2003-07-08 2004-07-08 Methodes de diagnostic et de traitement se rapportant au vieillissement (8a) WO2005005668A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002531420A CA2531420A1 (fr) 2003-07-08 2004-07-08 Methodes de diagnostic et de traitement se rapportant au vieillissement (8a)
EP04777802A EP1649063A2 (fr) 2003-07-08 2004-07-08 Methodes de diagnostic et de traitement se rapportant au vieillissement (8a)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48522203P 2003-07-08 2003-07-08
US60/485,222 2003-07-08

Publications (2)

Publication Number Publication Date
WO2005005668A2 true WO2005005668A2 (fr) 2005-01-20
WO2005005668A3 WO2005005668A3 (fr) 2005-09-09

Family

ID=34062070

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/021944 WO2005005668A2 (fr) 2003-07-08 2004-07-08 Methodes de diagnostic et de traitement se rapportant au vieillissement (8a)

Country Status (3)

Country Link
EP (1) EP1649063A2 (fr)
CA (1) CA2531420A1 (fr)
WO (1) WO2005005668A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025194A (en) * 1997-11-19 2000-02-15 Geron Corporation Nucleic acid sequence of senescence asssociated gene
WO2003000861A2 (fr) * 2001-06-22 2003-01-03 The Regents Of The University Of California Genes eucaryotiques impliques dans la regulation de la duree de vie adulte des eucaryotes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025194A (en) * 1997-11-19 2000-02-15 Geron Corporation Nucleic acid sequence of senescence asssociated gene
WO2003000861A2 (fr) * 2001-06-22 2003-01-03 The Regents Of The University Of California Genes eucaryotiques impliques dans la regulation de la duree de vie adulte des eucaryotes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
LIO D ET AL: "Gender-specific association between -1082 IL-10 promoter polymorphism and longevity" GENES AND IMMUNITY, vol. 3, no. 1, February 2002 (2002-02), pages 30-33, XP008039832 ISSN: 1466-4879 *
MERCHED A ET AL: "APOLIPOPROTEIN AIV CODON 360 MUTATION INCREASES WITH HUMAN AGING AND IS NOT ASSOCIATED WITH ALZHEIMER'S DISEASE" NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 242, no. 2, 13 February 1998 (1998-02-13), pages 117-119, XP000863724 ISSN: 0304-3940 *
MICHIKAWA Y ET AL: "Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 286, 22 October 1999 (1999-10-22), pages 774-779, XP002179334 ISSN: 0036-8075 *
MOCCHEGIANI EUGENIO ET AL: "MTmRNA gene expression, via IL-6 and glucocorticoids, as potential genetic marker of immunosenescence: Lessons from very old mice and humans" EXPERIMENTAL GERONTOLOGY, vol. 37, no. 2-3, January 2002 (2002-01), pages 349-357, XP002312292 ISSN: 0531-5565 *
ZHOU YIHUA ET AL: "A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse)" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 94, no. 24, 25 November 1997 (1997-11-25), pages 13215-13220, XP002312293 ISSN: 0027-8424 *

Also Published As

Publication number Publication date
EP1649063A2 (fr) 2006-04-26
CA2531420A1 (fr) 2005-01-20
WO2005005668A3 (fr) 2005-09-09

Similar Documents

Publication Publication Date Title
Ilyin et al. Comparative analysis of mouse hepcidin 1 and 2 genes: evidence for different patterns of expression and co-inducibility during iron overload
Kure et al. Comprehensive mutation analysis of GLDC, AMT, and GCSH in nonketotic hyperglycinemia
EP0973895B1 (fr) Facteur de transcription ilot-cerveau 1 (ib1)
JP2007289196A (ja) 癌組織でディファレンシャルに発現される核酸配列
US20070111933A1 (en) Diagnosis and treatment methods related to aging, especially of liver
Pucci et al. Preclinical and clinical evidence for a distinct regulation of mu opioid and type 1 cannabinoid receptor genes expression in obesity
WO2005082398A2 (fr) Diagnostic d'hyperinsulinemie et du diabete de type ii et protection contre lesdits etats pathologique grace aux genes exprimes de façon differentielle dans les cellules musculaires
Jung et al. Osteocalcin is incompletely spliced in non-osseous tissues
WO2006023121A1 (fr) Diagnostic d'hyperinsulinemie et de diabete de type ii et protection contre ceux-ci a base de genes differentiellement exprimes dans le tissu adipeux blanc (13)
JP2006508642A (ja) 脂肪の蓄積を減少させる方法と、関連疾患を治療するための方法
US20050031605A1 (en) Compositions and methods of treating diabetes
WO2005110460A2 (fr) Méthodes de traitement et diagnostics relatifs au vieillissement, particulièrement celui des muscles (14.1)
US20070142311A1 (en) Diagnosis of hyperinsulinemia and type II diabetes and protection against same
JP2007528707A (ja) 統合失調症の診断および治療のための標的としてのｅｇｒ遺伝子
EP1649063A2 (fr) Methodes de diagnostic et de traitement se rapportant au vieillissement (8a)
WO2005046718A1 (fr) Diagnostic de l'hyperinsulinemie et du diabete de type ii et protection contre ces maladies sur la base de genes d'expression differentielle dans des cellules pancreatiques (12.1)
Klugman Uncovering a novel role for BIRC6 in a dwarf mutant mouse
WO2004092419A2 (fr) Diagnosis de l'hyperinsulinemie et du diabette de type ii et protection correspondante (i)
Lecanda et al. Impaired intramembranous bone formation in connexin43 null mice
US20060240500A1 (en) Diagnosis of kidney damage and protection against same
US8138307B2 (en) Parkin interacting polypeptides and methods of use
Lee et al. eIF2B Activator Rescues Neonatal Lethality of an eIF2Bα Sugar Phosphate Binding Mutation Associated with Vanishing White Matter Disease
JP2007029019A (ja) 糖尿病関連遺伝子、およびその利用
Mohan et al. Molecular Mechanisms of Soft Tissue Regeneration and Bone Formation in Mice: Implications in Fracture Repair and Wound Healing in Humans
US20130059778A1 (en) Identification of a Genetic Risk Factor for Diabetes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2531420

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004777802

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004777802

Country of ref document: EP